SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions September class, title,number 09/09

20090238754 - Use of pyrene to carry peptides across the blood brain barrier: Described are methods for delivering a peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a peptide agent and pyrene, and related detection and therapeutic methods.... Agent: Foley And Lardner LLP Suite 500

20090238755 - Treatment and diagnosis of cancer: Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate... Agent: Proskauer Rose LLP

20090238756 - Image-guided therapy of myocardial disease: composition, manufacturing and applications: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular... Agent: Fulbright & Jaworski L.L.P.

20090238757 - Methods and compositions for administering therapeutic and diagnostic agents: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.... Agent: Immunomedics, Inc.

20090238758 - Random and non-random alkylene oxide polymer alloy compositions: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block... Agent: Nixon & Vanderhye, PC

20090238759 - Method of rapid methylation of alkene compound and kit for pet tracer preparation using the same: To provide a method of rapid methylation of alkenes, which is applicable to the preparation of a PET tracer and which enables alkenes to be methylated through cross coupling between SP2 (alkenyl) and SP3 (alkyl) carbon atoms rapidly and in a high yield. Methyl iodide and an alkenyltrialkylstannane are subjected... Agent: Quarles & Brady LLP

20090238760 - Antispermatogenic, spermicidal and/or antifungal composition and methods of using the same: Hexahydroindenopyridine compounds are disclosed which act as contraceptive agents by disrupting spermatogenesis, acting as spermicides or sperm motility inhibitors and/or act as antifungals; antispermatogenic, sperm motility inhibitors, spermicidal or antifungal compositions containing the compounds; and methods for disrupting spermatogenesis, inhibiting sperm motility, killing motile sperm or treating fungi using the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090238761 - Novel aryl piperazine derivatives with medical utility: This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, D2-like and 5-HT2 receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders incl. schizophrenia.... Agent: Birch Stewart Kolasch & Birch

20090238763 - High penetration compositions and uses thereof: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or... Agent: Perkins Coie LLP

20090238762 - Method for treating joint damage: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles... Agent: Goodwin Procter LLP

20090238764 - Diagnostic therapeutic method: t

20090238767 - Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy: This invention discloses a method of synthesizing targeting contrast agents for molecular imaging and targeting diagnosis and therapy, targeting contrast agents and targeting therapeutic agents and their use.... Agent: Philips Intellectual Property & Standards

20090238768 - Multimeric magnetic resonance contrast agents: The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).... Agent: Ge Healthcare, Inc.

20090238766 - Bioluminescent construct: The invention provides a construct comprising an amino acid sequence attached to a luciferin substrate, wherein the amino acid sequence is not a substrate for either luciferase or caspase-3/7 to render the substrate inactive in the presence of luciferase. The construct is useful, for example, as a negative control for... Agent: Paul D. Yasger Abbott Laboratories

20090238765 - Fluorescent contrast agent: The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes.... Agent: Ge Healthcare, Inc.

20090238769 - Compositions comprising nonionic and zwittterionic surfactants: An foaming agent comprising a non-ionic surfactant, zwitterionic surfactant, and free of anionic surfactants which is suitable for use in personal care products, e.g., dentifrice compositions, e.g., for use in the treatment and/or alleviation of xerostomia.... Agent: Colgate-palmolive Company

20090238770 - Organic compounds: in free or salt or solvate form, where W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification, and (B) one or more of compounds selected from the group consisting of A2A agonists, A2B antagonists, antihistamines, caspase inhibitors, ENaC inhibitors, LTB4... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090238771 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090238772 - Methods and compositions for prevention or treatment of rsv infection: Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by... Agent: Alnylam/fenwick

20090238775 - Mono-, di- and polyol alkoxylate phosphate esters in oral care formulations and methods for using same: This invention relates to a composition useful as an oral care composition comprising an organophosphate material, additional oral care composition ingredients, for example, a surfactant agent, and optionally an abrasive agent.... Agent: Novak Druce + Quigg, LLP

20090238774 - Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation: The invention herein relates to the use of nonpathogenic, anti-inflammatory and anti-bleeding lactic acid bacteria strains, and products and methods using such strains for treatment and prophylaxis of bleeding gum and gingivitis caused by oral inflammation.... Agent: Lynn E Barber

20090238773 - Use of morpholino compounds for the treatment of halitosis: Use of a morpholino compound having the general formula (I) wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090238776 - Oral care compositions and methods: The present invention relates to oral care compositions. The oral care compositions include an adhesive component and an oral care active, and are combined with a viscosity index improver and/or a water insoluble component. The present invention is also directed to methods relating to the oral care compositions.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090238777 - High fluoride ion recovery compositions: Compositions having high fluoride ion recovery comprising a hydrocolloid, a heteropolysaccharide, a PVME/MA copolymer, and a fluoride ion source and use thereof, e.g., in the treatment of xerostomia and/or sensitive teeth.... Agent: Colgate-palmolive Company

20090238779 - Dental treatment compositions and conformable dental treatment trays using the same: The present invention is a formable dental treatment tray utilizing poly(2-ethyl-2-oxazoline) and a gelatinous active. Blending of the active is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with an active ingredient, such as a peroxide like hydrogen peroxide, carbamide peroxide, sodium perborate, or sodium percarbonate, usually also with water or an appropriate... Agent: Geoffrey E. Dobbin, Patent Attorney

20090238778 - Tooth whitening compositions, delivery systems and methods: The present invention is directed to tooth whitening compositions that are capable of being activated by light energy, where the compositions include a safe and effective amount of riboflavin or a derivative of riboflavin, from about 0.1 to about 50 percent by weight of a bleaching agent and a water-soluble... Agent: Philip S. Johnson Johnson & Johnson

20090238780 - Amla extract for transdermal application: An extract of Emblica officinalis (Amla). Transdermal formulation having an extract of Emblica officinalis having exhibiting greater migration of Vitamin C across a skin surface as compared to a transdermal formulation having Vitamin C without the extract. Extract of Emblica officinalis exhibiting greater migration of H+ ions across a skin... Agent: Jyoti C. Iyer

20090238782 - Cosmetic composition which includes at least one polysaccharide derived from bacteria of hydrothermal origin: The invention relates to a cosmetic composition which includes at least one polysaccharide derived from bacteria of hydrothermal origin. This polysaccharide can consist of an exopolysaccharide which is derived from fermenting the said bacteria. This composition can be applied, in particular, to everyday care products for all types of skin.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090238781 - Polyglycerin-modified silicone and a cosmetic comprising the same: e

20090238783 - Treatment and composition for achieving skin anti-aging benefits by corneum protease activation: Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing... Agent: Fulbright & Jaworski L.L.P.

20090238784 - Novel unsaturated fatty hydroxy acid derivatives and the dermocosmetologic use thereof: The invention relates to unsaturated fatty hydroxy acid derivatives of formula (I), wherein Rn is independent from each other H or linear or branched alkyl group which contain from 1 to 6 carbon atoms and which are possibly substituted by a halogen atom, in particular a fluorine atom, R1 is... Agent: Birch Stewart Kolasch & Birch

20090238786 - Cosmetic formulations including solid antiperspirants: Cosmetic compositions such as solid antiperspirants and method for their manufacture are described. One such composition includes 1-25 weight percent of an antiperspirant drug active and 10-40 weight percent water. The composition also includes 25-60 weight percent of a humectant and 5-20 weight percent of a fatty acid. The composition... Agent: Konrad Raynes & Victor, LLP

20090238785 - Novel aldehydic musks and derivatives thereof: A compound comprising a Schiffs base of an aldehydic musk aromachemical with a substantially nonvolatile, odorless amine, wherein the imine moiety of said Schiffs base compound is stable against oxidation to a carboxyl group or a mixture of said compounds; said Schiffs base compound being biodegradable over time to said... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090238787 - Odour-reducing substances: c

20090238788 - Delivery of hydrogels as sprays: A method for delivering β-sheet peptide hydrogels to a target surface by shear-thinning and spraying the peptide hydrogel on the surface is provided. The β-sheet peptide hydrogels can be applied over a range of thicknesses and can cover broad surface areas. The β-sheet peptide hydrogels may also include a therapeutic... Agent: Ratnerprestia

20090238791 - Il-15ralpha sushi domain as a selective and potent enhancer of il-15 action through il-15beta/gamma, and hyperagonist (il-15ralpha sushi - il-15) fusion proteins: The present invention relates to the stimulation of the IL-15R beta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at... Agent: Young & Thompson

20090238789 - Modified erythropoietin polypeptides and uses thereof: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided... Agent: K&l Gates LLP

20090238792 - Suppression of postoperative ileus: The invention provides a method for suppressing postoperative ileus in connection with the performance of a surgical procedure on a patient. In accordance with the inventive method, interleukin-10 (IL-10), glycine, a COX-2 inhibitor and a mast cell stabilizer are administered to the patient undergoing the surgical procedure in an amount... Agent: Leydig Voit & Mayer, Ltd

20090238793 - Toll like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.... Agent: Crowell & Moring LLP Intellectual Property Group

20090238794 - Fluorinated macrocyclic compounds as hepatitis c virus inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090238795 - In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13... Agent: Morris Manning Martin LLP

20090238807 - Cell line: The invention provides a cell line complementing HSV ICP4, ICP27, and UL55 genes.... Agent: Leydig Voit & Mayer, Ltd

20090238805 - Methods and compositions for increasing rna interference: The present invention relates to compositions containing a combination of a first active component comprising one or more sulfated polysaccharides and/or glycosaminoglycans and a second active component comprising one or more RNAi-inducing molecules, and methods for using these compositions to enhance double-stranded RNA (dsRNA)-mediated gene silencing in pest or pathogen... Agent: Wolf Greenfield & Sacks, P.C.

20090238806 - Treatment of intervertebral disc degeneration: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.... Agent: Jhk Law

20090238804 - Use of cells containing a specific dna molecule as cytopathic agents to inhibit the proliferation of cells: The present invention relates to the use of cells containing in their genome a specific DNA molecule, as cytopathic agents able to inhibit the proliferation of cells, when these proliferative cells are contacted with the cells containing the above-mentioned DNA molecule.... Agent: Young & Thompson

20090238796 - Preparation for treatment of non-infectious inflammatory intestinal diseases: The invention relates to medicine and can be used for treating non-infectious inflammatory intestinal diseases to enhance efficiency of the non-infectious inflammatory intestinal disease treatment and reduce the length, the inventive preparation contains 5-aminosalicylic acid (5 ASA) or a substance, which decomposes in the organism that 5 ASA is formed,... Agent: Lauson & Tarver LLP

20090238797 - Nicotine-carrier vaccine formulation: The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulations comprising a nicotine-carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at... Agent: Novartis Corporate Intellectual Property

20090238801 - Amnion-derived stem cells and uses thereof: The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090238799 - Conditionally-immortalised pancreatic cells: Conditionally immortalized pancreatic cells are produced which remain immortal in the presence of 4-hydroxytamoxifen (4-OHT) but express normal pancreatic cell markers when 4-OHT is not present. The cells therefore permit cell lines to be constructed to produce cells useful for transplantation or in screening assays.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090238803 - Human cord blood derived unrestricted somatic stem cells (ussc): n

20090238802 - Intraperitoneal delivery of genetically engineered mesenchymal stem cells: A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia,... Agent: Mcandrews Held & Malloy, Ltd

20090238800 - Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues: The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal... Agent: Cozen O'connor, P.C.

20090238798 - Nucleotide sequences encoding insecticidal proteins: The present invention provides nucleotide sequences encoding an insecticidal protein exhibiting lepidopteran inhibitory activity, as well as a novel insecticidal protein referred to herein as a Cry1A.105 insecticide, transgenic plants expressing the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.... Agent: Monsanto Company

20090238809 - Application methods to rapidly alter disease and injury states using molecular transport of b6: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples... Agent: Mathew J. Temmerman

20090238810 - Ophthalmic composition: An ophthalmic composition is provided which is capable of enhancing a barrier function of a lipid layer that constitutes a tear film, for thereby restricting and curing corneal disorders such as dry eye. It is also an object of the invention to provide the ophthalmic composition with anti-inflammatory and antimicrobial... Agent: Burr & Brown

20090238808 - Process for the identification of novel enzyme interacting compounds: The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods... Agent: Clark & Elbing LLP

20090238811 - Enzymatic antimicrobial and antifouling coatings and polymeric materials: Disclosed herein are a coating, a textile finish, a wax, elastomer, a filler, an adhesive, or a sealant, as well as polymeric materials such as a plastic, a laminate, a composite, that includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase) alone or... Agent: C. Steven Mcdaniel C/o Daffer Mcdaniel, LLP

20090238812 - Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery: A method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST, specific for the distal region of the... Agent: Birch Stewart Kolasch & Birch

20090238813 - Compositions and methods for engineered human arginine deiminases: The present invention discloses the engineering of a human enzyme with arginine hydrolytic activity suitable for human therapy. An enzyme comprising of a human sequence is not likely to induce adverse immunological responses and thus is expected to constitute a superior therapeutic. Since the human genome does not encode arginases... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090238814 - Compositions and methods for treating hypophosphatasia: The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP... Agent: Randolph Bretton

20090238790 - Compounds and pharmaceutical compositions for the treatment of viral infections: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.... Agent: Jones Day

20090238817 - Anti-cell proliferative compounds and methods of use: The invention provides compounds such as proteins, peptides, peptidomimetics and small molecules, methods for treating cell proliferative disorders such as neoplasia, tumor, or cancer, and metastasis thereof, and methods for identifying and screening for active compounds.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090238818 - Induction of antigen specific immunnologic tolerance: Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from... Agent: Marshall, Gerstein & Borun LLP

20090238816 - Method for immunizing an avian species: The present invention relates to a method for generating a plurality of different IgY antibodies, by immunizing each of a plurality of avian organisms of the same or different species with a composition comprising a plurality of different antigens, thereby generating a plurality of different IgY antibodies.... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090238815 - Nondegradable hydrogels for medical device application: Disclosed are nondegradable hydrogels used to coat or form at least a portion of a medical device. The hydrogels may be formed from functionalized PEG based macromers. These hydrogels are easy to sterilize, transport and store. Methods of forming these hydrogels as described herein are included.... Agent: Medtronic Vascular, Inc.IPLegal Department

20090238819 - Therapeutic and diagnostic agents: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter... Agent: Knobbe Martens Olson & Bear LLP

20090238820 - Anti-madcam antibody compositions: The present invention relates to anti-MAdCAM antibody compositions comprising a chelating agent, and methods of treating inflammatory disease in a subject.... Agent: Pharmacia Corporation Global Patent Department

20090238823 - Antigen binding proteins capable of binding thymic stromal lymphopoietin: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and... Agent: Amgen Inc. Law Department

20090238824 - Breast, gastric and prostate cancer associated antigens and uses therefor: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention... Agent: Wolf Greenfield & Sacks, P.C.

20090238822 - Chimeric hepatitis c virus antigens for eliciting an immune response: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or... Agent: Sheridan Ross PC

20090238828 - Combinations for the treatment of diseases involving cell proliferation: wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090238821 - Humanized antibodies that sequester amyloid beta peptide: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.... Agent: Mcandrews Held & Malloy, Ltd

20090238826 - Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on... Agent: Nixon & Vanderhye, PC

20090238825 - Novel rabbit antibody humanization methods and humanized rabbit antibodies: The present invention is directed to novel and improved methods for humanizing rabbit heavy and light variable regions. The resulting humanized rabbit heavy and light chains and antibodies and antibody fragments containing are well suited for use in immunotherapy and immunodiagnosis as they retain the antigen binding affinity of the... Agent: Hunton & Williams LLP Intellectual Property Department

20090238827 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Dechert LLP

20090238829 - Stabilized single domain antibodies: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods... Agent: Wolf Greenfield & Sacks, P.C.

20090238830 - Protein: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.... Agent: Klauber & Jackson

20090238834 - Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer: The present invention provides methods and compositions for screening, diagnosis and prognosis of HCC, glioblastoma and lung cancer, for monitoring the effectiveness of HCC, glioblastoma and lung cancer treatment, and for drug development.... Agent: Klauber & Jackson

20090238831 - Monoclonal antibodies and uses thereof: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.... Agent: Paul D. Yasger Abbott Laboratories

20090238832 - Novel compositions and method for the treatment of psoriasis: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090238833 - Protein: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer or lung cancer, for monitoring the effectiveness of colorectal cancer or lung cancer treatment, and for drug development.... Agent: Klauber & Jackson

20090238835 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Dechert LLP

20090238836 - Hip kinase for fertility control: The present invention relates to the use of a pharmaceutical composition which comprises as active component at least one HipK4 nucleic acid, a HipK4 polypeptide, modulators of HipK4, antibodies directed against HipK4, a HipK4 antisense, and a HipK4 RNAi, for the diagnosis and treatment of fertility impairments and for contraception.... Agent: Millen, White, Zelano & Branigan, P.C.

20090238837 - High affinity siglec ligands: The invention relates to high affinity Siglec ligands that are useful for isolating cells that express Siglecs and for delivering agents to cells that express Siglecs. In one embodiment, the invention provides a method for treating cancer in a mammal that involves administering a Siglec ligand of the invention to... Agent: Schwegman, Lundberg & Woessner, P.A.

20090238838 - Insulinotropic peptide conjugate using an immunoglobulin fc: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has... Agent: Seed Intellectual Property Law Group PLLC

20090238839 - Somatic transgene immunization and related methods: The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin... Agent: Morgan, Lewis & Bockius, LLP

20090238840 - Therapeutic vaccine: In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in an organism, but particularly within an animal, particularly a mammal or a human, which is capable of preventing or alleviating amyloidosis, or the symptoms associated with amyloidosis, a group... Agent: King & Spalding

20090238841 - Hiv vaccine formulations: Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject.... Agent: Novartis Vaccines And Diagnostics Inc.

20090238842 - Vaccine for preventing and treating porcine progressive atrophic rhinitis: The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragments of recombinant subunit Pasteurella multocida toxins (rsPMT) capable of eliciting the production of antibodies against. Pasteurella multocida associated with PAR, said fragments each having an amino acid sequence that substantially corresponds... Agent: Charles E. Baxley, Esquire

20090238843 - Recombinant mva capable of expressing structural hcv antigens: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention,... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090238844 - Porcine reproductive and respiratory syndrome virus strains and compositions: This invention relates to two attenuated strains of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic compositions comprising one or more strains of attenuated porcine reproductive and respiratory syndrome virus (PRRSV).... Agent: Intervet/schering-plough Animal Health

20090238845 - Encapsulated vaccines for the oral vaccination and boostering of fish and other animals: The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals.... Agent: Moore & Van Allen PLLC

20090238847 - Deodorant particle: Disclosed is a deodorant particle having a BET specific surface area of 10 m2/g or more that are obtained by copolymerizing a monomer system including a crosslinkable vinyl monomer and a vinyl monomer having a heteroaromatic ring. The deodorant particles may contain a metal ion. Also disclosed is a process... Agent: Birch Stewart Kolasch & Birch

20090238846 - S/o type external preparation: The present invention provides an external preparation which can improve a skin permeability of a hydrophilic medicine such as NSAID so that the medicine can act directly on a diseased area without passing through gastrointestinal tract or mucosa. The S/O type external preparation external preparation excellent in percutaneous absorbability of... Agent: Fitch, Even, Tabin & Flannery

20090238849 - Stretchable laminated sheet: A stretchable laminated sheet with hydrophilic properties, which particularly has an excellent feeling and stability in wearing and is capable of efficiently enhancing the effect and efficacy brought about by a liquid component on a skin or other object, when the stretchable laminated sheet is impregnated with the liquid component... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090238848 - Use of an extract of the orchid vanda coerulea as a skin hydrating agent: s

20090238850 - Antimicrobial materials: Materials, compositions, and medical devices for the treatment or prophylaxis of microbial, including bacterial, infections, comprising at least one water-insoluble ceramic compound and at least one metal species. Methods of making such materials, compositions and medical devices.... Agent: Diana Houston Smith & Nephew, Inc.

20090238851 - Antibacterial electronic device and method for manufacturing the same: The present invention relates to a method for manufacturing an antibacterial electronic device. The method includes the steps of: (1) dispersing antibacterial material into alcohol solution with a predetermined concentration to form an even mixture solution; (2) laying statically the even mixture solution for a predetermined period of time to... Agent: Wpat, PC Intellectual Property Attorneys

20090238853 - Hybrid biomedical device fabricated from biomaterials and coated with a natural extra cellular matrix (ecm) coating: The present invention relates to a hybrid biomedical device formed from a prefabricated biomedical device and coated with an extracellular matrix coating which is produced by directly culturing mammalian cells on the prefabricated biomedical device. The purposes of applying such an ECM coating is to regulate the biological and cellular... Agent: Qing Liu

20090238852 - Methods for controlling intracellular calcium levels associated with an ischemic event: Described herein are methods for controlling the intracellular calcium concentration in a subject prior to experiencing an ischemic event, while experiencing an ischemic event, or while suffering from ischemia. The methods comprise administering an effective amount of O-desulfated heparin to the subject. The methods described herein are also useful in... Agent: Alston & Bird LLP

20090238854 - Plasticizers for coating compositions: A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and/or a bioactive agent. The coating composition can form a coating on an implantable device. The implantable device can be used to treat or prevent a... Agent: Squire, Sanders & Dempsey LLP

20090238855 - Laminate sheet articles for tissue regeneration: The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090238856 - Polysulfone block copolymers as drug-eluting coating material: A polymeric composition comprising a polysulfone polymer and an elastomeric polymer for use as a coating composition for coating an implantable device, such as a DES, and methods of making and using the implantable device are provided.... Agent: Squire, Sanders & Dempsey LLP

20090238857 - Use of hydrophobic crosslinking agents to prepare crosslinked biomaterial compositions: The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bix(sulfosuccinimidyl) suberate, and dithiobis(succinimidylpropionate). Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents... Agent: Seed Intellectual Property Law Group PLLC

20090238858 - Compositions and methods for treating ophthalmic diseases: Degradable polymeric compositions containing water-insoluble drugs blended with copolymers of biocompatible diphenol compound monomer units with pendant carboxylic acid groups polymerized with biocompatible diphenol com-pound monomer units with pendant carboxylic acid ester groups and poly(alkylene oxide) blocks, wherein the molar fraction in the copolymer of biocompatible diphenol compound monomer units... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090238859 - Sinus delivery of sustained release therapeutics: The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a... Agent: Morrison & Foerster LLP

20090238860 - Adhesive patch less irritative to skin: Disclosed is an adhesive patch composed of an adhesive base agent and a supporting body wherein the adhesive base agent contains 3-30% by mass of a low-molecular-weight polyisobutylene and aluminum hydroxide and/or titanium oxide but not substantially containing water. Also disclosed is a skin irritation reducing agent used therefore. Further... Agent: Edwards Angell Palmer & Dodge LLP

20090238861 - Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.... Agent: Darby & Darby P.C.

20090238864 - Dna vaccines encoding heat shock proteins: The present invention is related to a method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 60 (HSP60), or an active fragment thereof, wherein the nucleic... Agent: Winston & Strawn LLP Patent Department

20090238865 - Lipid nanocapsules, preparation process and use as medicine: The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing... Agent: Foley And Lardner LLP Suite 500

20090238863 - Liposome composition for induction of immunity: It is an object of the present invention to provide a liposome composition which is able to allow the MHC class I and class II molecules of antigen-presenting cells to efficiently present an antigen substance. The present invention provides a liposome composition, which comprises an oligosaccharide-coated liposome and an antigen... Agent: Greenblum & Bernstein, P.L.C

20090238862 - Methods and compositions for seprase inactivation: The present invention relates to isolated nucleic acids encoding short hairpin RNAs that interfere with seprase mRNA expression, vector and host cells for expressing seprase mRNA interfering short hairpin RNAs, and methods of therapeutic use of the same for preventing further tumor invasation and metastasis.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20090238866 - Chewable capsules: The invention provides an orally administrable chewable capsule comprising a capsule shell enclosing an oil-in-water emulsion in which the aqueous phase is gelled, or an oil droplet-containing dried residue of such an emulsion.... Agent: Knobbe Martens Olson & Bear LLP

20090238867 - Nanoparticulate anidulafungin compositions and methods for making the same: Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090238868 - Abuse-resistant oral dosage forms and method of use thereof: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the... Agent: Woodcock Washburn LLP

20090238869 - Propranolol formulations: Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone or about 60:40 to about 75:25 of ethylcellulose:hydroxypropylmethylcellulose.... Agent: Cantor Colburn, LLP

20090238870 - Dividable galenical form allowing modified release of the active ingredient: Dividable galenical form for the modified release of active ingredient, wherein the non-subdivided galenical form and a portion of said form obtained by subdivision have identical dissolution profiles. Medicaments.... Agent: The Firm Of Hueschen And Sage

20090238871 - Pharmaceutical composition: A pharmaceutical composition comprising an ester of 4-(1-hydroxy-1-methylethyl)-2 propyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid characterized in that when exposed to 75% relative humidity at 40° in open dish for one month the total amount of related substances does not increase more than 1% is described.... Agent: Arent Fox LLP

20090238873 - Extended release formulation containing a wax: Extended release pharmaceutical formulations are disclosed wherein the formulations contain an extended release portion and an immediate release portion, the extended release portion comprising an active pharmaceutical ingredient and a wax. Methods of making such extended release pharmaceutical formulations are also disclosed.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090238872 - Chlorine dioxide releasing composite article: A composite article that includes a ClO2-producing material integrated into an organic matrix and methods of using the same are described. The organic matrix of the composite article is formable at a temperature under about 150° C., permits contact between an activating stimulus (e.g., water vapor and/or electromagnetic energy) and... Agent: Basf Catalysts LLC

20090238874 - Biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan: The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell... Agent: Pepper Hamilton LLP

20090238875 - Chitosan or hyaluronic acid-poly(ethylene oxide)-and chitosan-hyaluronic acid-poly(ethylene oxide)-based hydrogel and manufacturing method therefor: Disclosed are a chitosan-chitosan-polyethylene oxide hydrogel formed via covalent bonding between chitosan derivatives crosslinked with an acrylate or methacrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof; a hyaluronic acid-hyaluronic acid-polyethylene oxide hydrogel formed via covalent bonding between hyaluronic acid derivatives crosslinked with an acrylate... Agent: Harness, Dickey & Pierce, P.L.C

20090238877 - Agent for improving fine wrinkles: An agent for improving fine wrinkles contains an oil based preparation for external use for skins, the oil based preparation containing: (i) 50% by mass to 95% by mass of an oil constituent, which contains 10% by mass to 100% by mass of a solid or semisolid oil constituent, and... Agent: Rankin, Hill & Clark LLP

20090238876 - Bisphosphonates for treating endometriosis: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.... Agent: Cadwalader, Wickersham & Taft LLP

20090238882 - Carbon-substituted diketopiperazine delivery systems: Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided.... Agent: K&l Gates LLP

20090238879 - Delivery scaffolds and related methods of use: The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are... Agent: Casimir Jones, S.c.

20090238881 - Ionophore antibiotic formulations: The invention relates to an ionophore antibiotic composition capable of diluting with water to a substantially stable dispersed form in all water than present, said composition comprising or including:—at least one ionophore antibiotic (preferably monensin) of a mean particle size of less than 20 microns,—and at least one dispersing agent.... Agent: Eli Lilly & Company

20090238880 - Phospholipid-based pharmaceutical formulations and methods for producing and using same: Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid... Agent: Biogen Idec / Finnegan Henderson, LLP

20090238878 - Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances such as docetaxel with reduced Ostwald ripening.... Agent: Nanda P.b.a. Kumar Reed Smith LLP

20090238884 - Compositions for site-specific delivery of imatinib and methods of use: The invention provides an oral formulation for administering to a subject comprising an imatinib compound and an enteric matrix or enteric coating or a combination thereof, whereby at least 80% of the imatinib compound is released in the small intestine of the subject. Methods of using such formulation is also... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090238883 - Liver-specific nanocapsules and methods of using: This disclosure describes liver-specific nanocapsules for specifically targeting liver cells. This disclosure also provides methods of using such liver-specific nanocapsules to deliver one or more cargo moieties to the liver cells.... Agent: Swanson & Bratschun, L.L.C.

20090238885 - Protein encapsulated particles: Particles that are encapsulated by protein are provided. Also a method for preparing protein encapsulated particles involving spraying and drying of an activated protein solution is provided. The protein encapsulated particles are particularly suited for food, feed, cosmetic and pharma applications.... Agent: Foley And Lardner LLP Suite 500

20090238886 - Retro-inversion peptides that target git transport receptors and related methods: Retro-inverted forms of GIT targeting agents that target specific receptor sites in vivo and/or promote uptake of active agents and/or enhance active site delivery across the GIT into the systemic circulation are provided. These retro-inverted peptides and compositions containing these retro-inverted peptides can be used to deliver an active agent,... Agent: Myers Bigel Sibley & Sajovec

20090238887 - Highly impact-resistant granules: The present invention provides highly impact-resistant, water-soluble or water dispersible, low-dust granules comprising an active ingredient and methods for obtaining the same.... Agent: Danisco US Inc. Attention: Legal Department

20090238889 - Hyper-branched polymers for the provision of hygienic characteristics: The invention relates to hyper-branched polymers having a hydrophobic core and an antimicrobial and/or anti-adhesive active shell for providing surfaces with semi-permanent hygienic characteristics.... Agent: Ratner Prestia

20090238888 - Radical polymerization method and products prepared thereby: In one embodiment, the present invention relates to a method for initiating radical polymerization of at least one monomer composition, the method comprising the steps of: supplying at least one monomer charge; and initiating radical polymerization of the at least one monomer charge via a hydrogen peroxide initiator and at... Agent: Roetzel And Andress

20090238890 - Continuous spray-capture production system: The disclosure relates to novel microencapsulation processes based on the use of high viscosity fluids (e.g., gelatinized starch and alginate), which are mixed and then sprayed using a much gentler hydraulic pressure and, preferably gas-based atomization into a crosslinking solution (e.g. of calcium chloride). To improve the efficiency of the... Agent: Moore & Van Allen PLLC

20090238892 - Deer antler extract for promoting angiogenesis: An isolated extract of deer velvet which contains components which have molecular weights that are substantially are less than or equal to 10 kDa and which have a proliferative effect on endothelial cells and/or promote angiogenesis.... Agent: Knobbe Martens Olson & Bear LLP

20090238891 - Method of producing a dry earthworm powder: Provided is a method of producing a dry earthworm powder without deterioration in useful pharmacological action, by removing dirt on the skin of earthworms while allowing the earthworms to excrete the digest remaining in the digestive tracts efficiently without weakening the earthworms, which comprises the steps of: standing living earthworms... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090238893 - Nutritional formulation: A nutritional formulation for the treatment of inflammatory conditions of the gastrointestinal tract (particularly Crohn's Disease in paediatric patients) comprises: (a) a lipid source, (b) a carbohydrate source, and (c) a protein source. wherein the lipid source comprises a weight ratio of n-6:n-3 fatty acids of 1:1 to 3:1, at... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090238894 - Thrush and white line medicinal delivery system: An equine medicinal delivery system includes a dental roll impregnated with a medicinal solution for placement in an equine hoof. Another embodiment of an equine medicinal delivery system includes a pledget impregnated with a medicinal solution for placement in an equine hoof. A method of manufacturing an equine medicinal delivery... Agent: Quarles & Brady LLP

20090238895 - Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal: The invention dissolves the problem of the pharmaceutical preparation being a factor stimulating the absorption of microelements. The essence of the invention is that the preparation contains alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-keto-glutarate, dipeptide of glutamine and other amino acids or/and tripeptides of glutamine and other amino... Agent: Ladas & Parry LLP

20090238896 - Compositions and methods for diagnosing and treating melanoma: Described herein are compositions and methods for the diagnosis, prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma, as well as various nucleic acid molecules relating thereto or derived therefrom.... Agent: Darby & Darby P.C.

20090238897 - Removal of skin changes: The present invention relates to the field of skin disorders, particularly to the prevention and/or treatment of benignant or malignant changes of the epidermis visible in form of e.g. nevus. A pharmaceutical, dermatological and/or cosmetic composition is disclosed comprising as active constituent the boroxine compound. The present invention further provides... Agent: Knobbe Martens Olson & Bear LLP

20090238898 - Method of inhibiting the proliferation and migration of helicobactor pylori: Helicobacter pylori strains are indigenous to each human host and infect and colonize in the stomach of the host, and they are also known to be involved in diseases of the upper gastrointestinal tracts, among others. The present invention provides an economical method for inhibiting the proliferation and migration of... Agent: Knobbe Martens Olson & Bear LLP

20090238899 - Method for rapid identification of pharmacologically active chemical entities associated with the efficacy of ethnobotanical substances: The method includes the steps of performing in-vitro liver, intestinal and/or expressed enzyme assays with selected ethnobotanical substances, for both humans and a variety of animal species, to produce an array of resulting chemical entities, such as metabolites, for the human and the animals. Comparisons are then made between the... Agent: Jensen + Puntigam, P.s.

20090238901 - Method for treatment of constipation-predominant irritable bowel syndrome: The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation... Agent: King & Spalding

20090238900 - Novel anti-diabetic herbal composition, method for preparing the same and use thereof: Disclosed is an herbal composition for the treatment of Type II diabetes and their associated secondary complications in humans, wherein said composition comprising extract of roots of Cipadessa baccifera and pharmaceutically acceptable excipients, method for preparing the same and use thereof. The anti-diabetic herbal composition disclosed herein is effective to... Agent: Knobbe Martens Olson & Bear LLP

20090238902 - Chinese medicine composition and preparation method and use thereof: This invention relates a traditional Chinese medicine composition and the drug containing this composition as well as preparation method and use thereof. The composition comprises 1-10 parts by weight of radix ginseng, 1-10 parts by weight of folium ginkgo, 0.05-0.5 parts by weight of stigma croci and 5-10 parts by... Agent: Edwards Angell Palmer & Dodge LLP

20090238903 - Process for the preparation of sour cherry seed extract, use of the extract for the preparation of pharmaceutical compositions and pharmaceutical compositions containing said extract: The present invention relates to a process for the isolation of the components of seed of Primus cerasus (sour cherry), the components thus obtained, pharmaceutical compositions containing said components as well as the use of the components for the preparation of cardioprotective pharmaceutical compositions. The components according to the invention... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090238904 - Compositions and methods for promoting weight loss: Compositions, which include psyllium and polyethylene glycol in a weight ratio of psyllium to polyethylene glycol of from about 1:3 to about 2:1, a gum, and one or more additional ingredients selected from the group consisting of water, salt, sweeteners, flavoring agents, and preservatives are presented.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090238905 - Inflammation reducing action of synergistic mixtures of bisabolol and ginger extracts: A formulation for treating or eliminating irritation and/or inflammation-reducing effect on endodermal tissue of the respiratory tract, the gastrointestinal tract, or both is disclosed. The formulation can include bisabolol or an extract containing bisabolol and actives found in ginger or extracted from ginger. The ratio of bisabolol and actives from... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20090238906 - Flavor improving agent: f

20090238907 - Topical compositions containing bacillus coagulans extracellular products and uses thereof: The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090232731 - Cationic liposomal preparations for the treatment of rheumatoid arthritis: The present invention refers to the use of cationic liposomal preparations for the treatment or diagnosis of rheumatoid arthritis or related disorders.... Agent: Morgan Lewis & Bockius LLP

20090232730 - Method of producing immunoliposomes and compositions thereof: The invention provides a method for a multi-layered lipid particles in the form of liposomes that are coated first with a cryoprotectant followed by a targeting moiety over the coat of cryoprotectant, and a method for encapsulating drugs and agents in the multi-layered coated liposomes. In addition, ready-to-use liposome kits... Agent: David S. Resnick

20090232734 - Anti-tissue factor antibodies and compositions: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of... Agent: Philip S. Johnson Johnson & Johnson

20090232733 - Diagnostic and therapeutic potential of immune globulin intravenous (igiv) products: The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured... Agent: Morgan Lewis & Bockius LLP

20090232732 - Pro108 antibody compositions and methods of use and use of pro108 to assess cancer risk: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach... Agent: Licata & Tyrrell P.C.

20090232735 - Use of fructose-based therapies for the treatment of cancer: The methods and compositions of the invention are based on the preferential utilization of fructose by cancer cells. This invention relates to compositions, methods and kits utilizing fructose and other monosaccharides for the treatment of cancer. This invention also relates to methods and kits for using compositions to mimic or... Agent: Davis Wright Tremaine LLP/los Angeles

20090232736 - Dual specificity antibodies and methods of making and using: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of... Agent: Abbott Bioresearch

20090232738 - Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1 to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090232737 - Purification of proteins: The present invention relates to a selectively soluble polymer capable of binding to a desired molecules in an unclarified mixture containing various biological materials and the methods of using such a polymer to purify a molecule from such a mixture. The polymer is soluble in the mixture under a certain... Agent: Millipore Corporation

20090232739 - Method of in vivo screening for cardiac toxic agents using teleost: This invention relates to a method of screening agents for cardiotoxicity based on the observations of the alteration of heart rate and heart rhythm, using teleost embryos and larvae. This invention also relates to a method for identification of gene(s) related to cardiac functions in teleost.... Agent: Lawrence P. Casson Kenyon & Kenyon LLP

20090232740 - Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease: A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090232742 - Method for screening agent with angiogenic-modulating activities using teleost embryo: This invention relates to a method of 3-tier system for screening compounds, herb extract or extract of herb combination in formula with angiogenic-modulating activities using transparent teleost embryos as model.... Agent: Kenyon & Kenyon LLP

20090232741 - Optical imaging: This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of... Agent: Ge Healthcare, Inc.

20090232743 - Foamable microemulsion compositions for topical administration: Described are ethanol-free foamable microemulsions for topical application, and method of making them. The propellants used in the compositions may be environmentally-friendly hydrofluoroalkanes. The foam compositions may also comprise one or more of a variety of active ingredients, including anti-inflammatory agents, anesthetics, and keratolytic agents.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090232745 - Licorice lollipop that inhibits dental caries formation: This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.... Agent: Weaver Austin Villeneuve & Sampson LLP

20090232744 - Macrolide compositions having improved taste and stability: The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate,... Agent: Edwards Angell Palmer & Dodge LLP

20090232746 - Silicone polymer-silica system: A chemical system comprising amodimethicone, dimethicone gum and silica is provided. The chemical system is useful in varying concentrations in antiperspirants of any form, including, but not limited to, solid stick, aerosol spray and liquid roll-on. Embodiments of the invention further include a method for preparing a chemical composition comprising... Agent: Schwegman, Lundberg & Woessner, P.A.

20090232747 - Thioester compounds and their use in fragrance or flavor applications: The present invention relates to thioester compounds and the incorporation and use of the new chemical entities as flavor and fragrance chemicals.... Agent: International Flavors & Fragrances Inc.

20090232748 - Virucidal activities of cetylpyridinium chloride: This disclosure relates to inventive methods for inactivating viral pathogens comprising providing a virucidal composition comprising a liquid media containing less than 1% weight per volume of a quaternary ammonium compound, such as cetylpyridinium chloride and between 0% and 0.5% weight per volume of citric acid, and contacting a surface... Agent: Vinson & Elkins L.L.P.

20090232749 - Compositions for the acute and/or long term treatment of periodontal diseases: Composition comprising a mixture of radix polygoni multiflori, Fructus Corni, cuscuta japonica, rehmannia glutinosa, licorice, asparagine, Derla andrographis and a composition comprising a mixture of Salvida persica, achyranthes aspera, spilanthes acmela, clove, picus Bengalensis, acacia nilotioca resen, eucalyptus, mint, green tea, bamboo silica for the acute and/or long term treatment... Agent: Hoffmann & Baron, LLP

20090232755 - Combination therapies for treating photodamaged skin: Combination therapies for reducing the appearance of fine lines and wrinkles on aged skin or non-precancerous, normal photodamaged section of skin, in a patient not being treated for viral infection or skin cancer comprising (i) topical application of an imidazoquinoline amine derivative in a dermatologically-acceptable carrier in further combination with... Agent: Louis C. Paul

20090232750 - Compositions for indoor tanning: Compositions for inducing a natural tan of the skin is disclosed. The compositions contain D-ribose as the active ingredient plus a penetrant to deliver D-ribose to the basal cells and dermis of the skin. Compositions further containing emollients and emulsifiers are preferred.... Agent: Kathleen R. Terry

20090232754 - Enhanced photostability of suncare compositions containing avobenzone: The photostability of avobenzone in a sunscreen composition is stabilized against photodegradation using menthyl anthranilate.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090232753 - Gel compositions: Wherein n=1, 2, 3, and 4, and R1 represents a member of the group consisting of: hydrogen, hydrocarbyl, phenyl, methoxyphenyl, alkylphenyl, substituted alkyl, and substituted phenyl; R2 represents a member of the group consisting of: hydrogen, hydrocarbyl, phenyl, methoxyphenyl, alkylphenyl, substituted alkyl, substituted phenyl, alkylene, phenylene, substituted alkylene, and substituted... Agent: Arthur M. Dula

20090232751 - High sunscreen efficiency water-in-oil emulsion: The present invention relates to highly stable water-in-oil sunscreen emulsions that provide a high sunscreen efficiency (“SE”) having a sun protection factor (“SPF”) of X, where X is at least about 15, and having a sunscreen efficiency (“SE”) of at least 2, preferably at least 3, where SE is the... Agent: Louis C. Paul

20090232752 - Silicone polyurethane blends: The invention describes the unexpected characteristics of blends, including crosslinked reaction products of elastomeric silicone polymers with various polyurethanes and their applications in personal care products.... Agent: Coleman Sudol Sapone, P.C.

20090232756 - Cosmetic composition comprising an ascorbic acid or salicylic acid compound: e

20090232757 - Use of gamma-amino butyric acid as a depigmenting agent: Use of gamma aminobutyric acid, one of its salts or one of its lower alkyl ester or a polyol ester as depigmenting or melano modulating agent.... Agent: Hedman & Costigan P.C.

20090232758 - Brassocattleya marcella koss orchid extract and use thereof as skin depigmentation agent: This invention relates to an orchid extract of the Brassocattleya Marcella Koss variety, as well as the use thereof in compositions such as cosmetic compositions, intended to depigment the skin, in particular to lighten the complexion or to improve the uniformity of the skin coloring, or to correct or attenuate... Agent: Foley And Lardner LLP Suite 500

20090232759 - Hair treatment compositions: The invention provides a hair treatment composition comprising a combination of a sugar, an amine oxide and an amino acid. The composition is particularly suitable for the treatment of hair which is dry, damaged and/or prone to manageability problems.... Agent: Unilever Patent Group

20090232760 - Horse bedding product and method: wherein the enzyme powder comprises hydrolyzing enzymes, bacteria and bacterial growth medium and wherein the enzyme solution and the enzyme powder act on fecal and urinary materials to reduce odor, and the layer of rice hulls increases its absorbency as a function of the degree that it is crushed by... Agent: George S. Levy

20090232761 - Use of a composition comprising pentane-1, 5-diol as deodorant: In one embodiment of the present invention, the use of a composition is disclosed including pentane-1,5-diol to reduce and/or eliminate odour from a mammal, such as odour from such as urine, faeces, liquids from leg ulcers, decubital ulcers, blood and perspiration. One embodiment of the present invention also relates to... Agent: Harness, Dickey & Pierce, P.L.C

20090232763 - Aqueous pharmaceutical compositions containing borate-polyol complexes: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate, a preservative or both.... Agent: Alcon

20090232764 - Triblock polymers and polymer coatings: The invention provides novel polymers, including triblock polymers, as well as methods of preparing the polymers, and compositions that include such polymers. The polymers can include at least three blocks, the first block that includes poly(styrene), the second block that includes a random arrangement of poly(ethylene) and poly(butylene), and a... Agent: Schwegman, Lundberg & Woessner, P.A.

20090232762 - Compositions for delivery of therapeutic agents: The invention provides a polyamide compounds and compositions, in addition to methods for their preparation and methods for their use. The invention also provides micelle compositions that include encapsulated therapeutic agents, for example, nucleic acids or prodrugs, and methods for their preparation. The invention further provides methods of delivering therapeutic... Agent: Schwegman, Lundberg & Woessner, P.A.

20090232765 - Method for improved refuge efficiency: A method to improve the efficiency of refuge crops in preventing the development of insects that are resistant to an insecticide. The method involves using an attractant to lure insects to the refuge and increase the population of survivors. The protected crops include cotton and corn. The refuge crop may... Agent: Howrey LLP

20090232766 - Compositions for inducing immune response comprising inverted microsomes: A vaccine composition is provided which comprises inverted microsomes or fragments thereof from an animal cell in association with an externally disposed peptide antigen and a protein of the MHC.... Agent: Pepper Hamilton LLP

20090232767 - Methods and compositions based on diphtheria toxin-interleukin-3 conjugates: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388... Agent: Jones Day

20090232768 - Novel compounds and methods for therapy: e

20090232769 - Pharmaceutical composition for treatment of blood clotting disorder: Disclosed is a pharmaceutical composition for the prevention or treatment of blood clotting disorder which can reduce a burden on a patient. The pharmaceutical composition comprises an effective amount of ribavirin or a derivative thereof or a pharmaceutically acceptable salt of ribavirin or the derivative.... Agent: Oliff & Berridge, PLC

20090232784 - Endothelial predecessor cell seeded wound healing scaffold: Compositions and processes for promoting wound healing are provided by the present invention which increase the rate and completeness of wound healing. Broadly described, an inventive composition includes a degradable scaffold of biocompatible material and a cell involved in wound healing, or a predecessor of such a cell, disposed in... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090232785 - Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the prevention al and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least... Agent: Oliff & Berridge, PLC

20090232786 - Herbal composition for cancer treatment: A therapeutic herbal composition comprising Saw Palmetto, Bromelain, Willow Herb, Grape Seed Complex, Wild Rosella, Liquorice, Passionfruit Seed and Selenium Yeast is claimed. The composition may be used as a general health promotant but is also useful as a treatment of cancer and inflammation. Prostate cancer and hyperplasia may be... Agent: Sughrue Mion, PLLC

20090232770 - Process of production of bacteriophage compositions and methods in phage therapy field: A method for producing bacteriophage stock compositions including (a) incubating a culture medium including at least one bacterial strain, at least one bacteriophage strain that can infect the bacterial strain, and at least one antibiotic, wherein the concentration of the antibiotic in the medium is in a range which causes... Agent: Ip Group Of Dla Piper LLP (us)

20090232775 - Compounds and methods for increasing neurogenesis: The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed.... Agent: Ivor R. Elrifi, Esq. Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.

20090232780 - Compounds that enhance atoh1 expression: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g.,... Agent: Fish & Richardson PC

20090232777 - Expansion and differentiation of mesenchymal stem cells: A cell culture system for expanding and differentiating mammalian mesenchymal stem cells to chondrocytes is provided. Said cell culture system comprises a subpopulation of isolated MSC selected for their expression of integrin alpha 10, as well as additives promoting expansion and differentiation to chondrocytes. Methods and uses of said expanded... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090232772 - Human corneal endothelial cell-derived precursor cells, cellular aggregates, methods for manufacturing the same, and methods for transplanting precursor cells and cellular aggregates: Providing is cellular aggregates derived from corneal endothelial cells that, when transplanted, readily adhere to the parenchyma of cornea and function in a manner equivalent to corneal endothelial cells, and a method of transplantation of the cellular aggregates. Cellular aggregates derived from corneal endothelial cells. The cellular aggregates derived from... Agent: Greenblum & Bernstein, P.L.C

20090232773 - Method for distinguishing mesenchymal stem cell using molecular marker and use thereof: Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem... Agent: Harness, Dickey & Pierce, P.L.C

20090232783 - Method for regulating production of hemoglobin beta chains: A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer.... Agent: Dunlap Codding, P.C.

20090232782 - Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells: A method for treating or preventing an ischemic brain injury or neurological damage due to ischemia in a subject includes transplanting a therapeutically effective amount of human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the ischemic areas of the brain injury or the neurological damage of the... Agent: Panitch Schwarze Belisario & Nadel LLP

20090232771 - Method of controlling cell functions: The present invention provides methods of screening genes associated with cell regeneration, growth and differentiation and regulators for cell regeneration, growth or differentiation; regulators for cell regeneration, growth or differentiation; and so on. More specifically, the present invention provides methods of screening genes associated with cell regeneration, growth and differentiation,... Agent: Edwards Angell Palmer & Dodge LLP

20090232778 - Methods and compositions for hair growth: Methods and compositions for identifying and isolating dermal papilla cells are described. DP cells can be identified based on corin expression. Isolated DP cells can be used, e.g., to modulate hair growth.... Agent: Fish & Richardson PC

20090232779 - Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury: This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of... Agent: Bozicevic, Field & Francis LLP

20090232781 - Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells: A method for treating liver diseases or liver damage, including but not limited to liver fibrosis, and/or aiding recovery from liver diseases, including but not limited to liver fibrosis, or liver damage in a subject, includes transplanting human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the area... Agent: Panitch Schwarze Belisario & Nadel LLP

20090232774 - Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance: The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090232776 - Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction: Methods of treating, preventing or managing endothelial dysfunction and other disorders are disclosed. The methods encompass the administration of an immunomodulatory compound provided herein. Further described are methods of treatment using the immunomodulatory compounds in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms suitable for... Agent: Jones Day

20090232787 - Carcinogen detoxification composition and method: A pharmaceutical, food or cosmetic composition comprising a carrier and an effective amount of an active benzo(a)pyrene binding protein, whereby the protein is a SAM-dependent methyltransferase or a function-conservative variant or fragment thereof, having a SAM-binding domain specifically binding benzo(a)pyrene.... Agent: Alston & Bird LLP

20090232788 - Enzyme with microbial lysis activity from trichoderma reesei: The invention provides fungal polypeptides from Trichoderma reesei that possess anti-microbial activity, polynucleotides encoding the polypeptides, compositions comprising the polypeptides and polynucleotides, and methods of use, thereof.... Agent: Danisco US Inc. Attention: Legal Department

20090232789 - Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC

20090232790 - Kit of lyophilized thrombin and lyophilized fibrinogen used to compound fibrin membrane, and its application: A kit of lyophilized thrombin and lyophilized fibrinogen comprises fibrinogen of 50-100 mg/ml, thrombin of 100-1000 IU/ml and 20-60 mmol/L CaCl2 used to compound fibrin membrane. The lyophilized thrombin and lyophilized fibrinogen are applied in a clinical tumor operation for reducing the risk of tumor metastasis after the operation. The... Agent: Merek, Blackmon & Voorhees, LLC

20090232791 - Methods and compositions for tissue regeneration: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.... Agent: Fulbright & Jaworski L.L.P.

20090232792 - Antimicrobial carbon: The present invention relates to antimicrobial carbon and to its use, especially for treating diseases and toxications of the gastrointestinal tracts, in particular diarrhoea.... Agent: Millen, White, Zelano & Branigan, P.C.

20090232795 - 1b20 pcsk9 antagonists: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host... Agent: Merck And Co., Inc

20090232793 - Elastase inhibitor and acute leukemia: The invention relates to the use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia, preferably acute leukemia and more preferably for the treatment of AML... Agent: Marshall, Gerstein & Borun LLP

20090232796 - Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand: Provided herein relates to the field of cancer and its treatment by administering immunomodulatory compounds in combination with other compounds. In particular, a combination of an immunomodulatory compound and an anti-CD40 antibody and/or a CD40 ligand is provided.... Agent: Jones Day

20090232798 - Methods and compositions for treating herpes infections: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090232794 - Modulators of neuronal regeneration: The present invention provides methods and compositions related to CNS function and diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090232797 - Plasmodium malariae and plasmodium ovale genes and uses thereof: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.... Agent: Paul D. Yasger Abbott Laboratories

20090232806 - Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological... Agent: Townsend And Townsend And Crew LLP

20090232799 - Antibodies that bind urokinase-type plasminogen activator and epitopes therefor: Anti-uPA antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind uPA epitopes and activate uPA function, such as inhibition of uPA mediated inflammation. Epitopes that can be used... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090232803 - Antibodies to human il-1beta: An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis... Agent: Novartis Corporate Intellectual Property

20090232802 - Compositions and methods for the treatment of natural killer cell related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090232800 - E1-minus adenoviruses and use thereof: e

20090232804 - Humanized antibodies specific for von willebrand factor: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.... Agent: K&l Gates LLP

20090232801 - Humanized antibodies which bind to ab (1-42) globulomer and uses thereof: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.... Agent: Paul D. Yasger Abbott Laboratories

20090232805 - Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist: The present invention relates to methods of inhibiting receptor tyrosine kinases by utilizing a combination of both an extracellular and an intracellular RTK antagonist. The extracellular RTK antagonist is a biological molecule or a small molecule that inhibits activation of the receptor tyrosine kinase by interacting with the extracellular binding... Agent: Kenyon & Kenyon LLP

20090232807 - Glp-1 analog fusion protein formulations: The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described... Agent: Eli Lilly & Company

20090232810 - Immunoconjugates targeting cd138 and uses thereof: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090232808 - Molecules and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof... Agent: Seed Intellectual Property Law Group PLLC

20090232809 - Type 2 cytokine receptor and nucleic acids encoding same: The present invention provides novel isolated CRF2-13 polynucleotides and polypeptides encoded by the CRF2-13 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-13 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-13 polypeptide, polynucleotide or antibody. The invention additionally provides methods in... Agent: Wyeth/latimer, Mayberry & Matthews, LLP

20090232811 - Bivalent, bispecific antibodies: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090232812 - Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom: The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and for the treatment of tumors with antagonists of the binding of ligands to the extracellular domain of MUC1, such binding being related to an oncogenic function of MUC1.... Agent: Fulbright & Jaworski L.L.P.

20090232814 - Cancer biomarker genes and gene products and methods for using the same: Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating... Agent: Licata & Tyrrell P.C.

20090232813 - Four-jointed box (fjx1) in cancer diagnosis and treatment: The present invention relates to a new tumor suppressor, designated FJX1. Also described are diagnostic, prognostic and therapeutic uses of the FJX1 protein and the FJX1 gene, alone or in combination with traditional cancer therapies.... Agent: Fulbright & Jaworski L.L.P.

20090232823 - Anti-tyrp1 antibodies: The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides... Agent: Eli Lilly & Company

20090232815 - Antibodies that bind to pleiotrophin growth factor receptor: This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further,... Agent: Ropes & Gray LLP

20090232817 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090232824 - Bivm (basic, immunoglobulin-like variable motif-containing) gene, transcriptional products, and uses thereof: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs: 1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090232816 - Il-1 eta dna and polypeptides: The invention is directed to novel purified and isolated IL-1 eta polypeptides and fragment thereof, the polynucleotides encoding such, polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.... Agent: Immunex Corporation

20090232822 - Lung disease targets and uses thereof: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung diseases (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as... Agent: Celera Corporation

20090232819 - Method using snail transcriptional repressor: Provided is a prognostic molecular marker for breast cancer recurrence. Expression of Snail, a zinc finger transcriptional repressor gene, is correlated to the risk of breast cancer recurrence, and to the likelihood of recurrence-free survival in subjects diagnosed with breast cancer. Further provided are methods of identifying therapeutic compositions for... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090232825 - Methods and compositions for modulating immunity: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090232820 - Neisseria meningitidis antigens and compositions: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.... Agent: Novartis Vaccines And Diagnostics Inc.

20090232818 - Prognosis and treatment of breast cancer: The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis... Agent: Licata & Tyrrell P.C.

20090232821 - Use of a growth-stimulating protein: This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing or treating other hyperproliferative diseases in an individual, by down regulating... Agent: Birch Stewart Kolasch & Birch

20090232826 - Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2: The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID... Agent: Oliff & Berridge, PLC

20090232827 - Compositions and methods of use of compounds to increase cancer patient survival time: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention... Agent: Scott A. Whitaker, Ph.d., J.d., Senior Intellecual Property Counsel

20090232828 - Methods of using igfir and abl kinase modulators: The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090232829 - Methods and compositions for treating inflammatory conditions: The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions... Agent: Nixon Peabody LLP - Patent Group

20090232831 - Methods and compositions for the treatment or prevention of human immunodeficiency virus infection: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the... Agent: Luce, Forward, Hamilton & Scripps LLP

20090232830 - Modified hiv-1 envelope proteins: The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes.... Agent: Morgan Lewis & Bockius LLP

20090232832 - Polyclonal antiserum against a universal tumor antigen: The present invention relates to a polyclonal antiserum against a universal tumor antigen obtainable by (i) eliciting an in vivo humoral response against embryonic tissue in a non-human vertebrate, whereby said embryonic tissue is of the same genetic line as the non-human vertebrate; (ii) recovering from the immunized non-human animal... Agent: Foley And Lardner LLP Suite 500

20090232833 - Polyalkylene oxides having hindered ester-based biodegradable linkers: The present invention provides polymeric delivery systems including hindered ester moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090232835 - Composition for delivery of hematopoietic growth factor: A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first... Agent: Marsh, Fischmann & Breyfogle LLP

20090232834 - Methods and agents to treat autoimmune diseases: A therapeutic method for preventing, suppressing, or treating an autoimmune disease is described. This method involves administering to a patient suffering from an autoimmune disease an effective amount of a composition containing an allogeneic or autologous leucocyte cell population derived from a healthy donor. The composition is administered by subcutaneous... Agent: Pearl Cohen Zedek Latzer, LLP

20090232836 - Vaccine compositions for inducing immune responses against components of drusen: Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090232837 - Anti tumoral immunogenic peptides and vaccine thereof: The invention relates to novel, Frizzled-like, immunogenic peptides, useful for the stimulation of an immune response against various cancer types, particularly colon rectal carcinoma.... Agent: Darby & Darby P.C.

20090232838 - Ligands of melanocortin receptors: The present invention is directed to a compound according to formula, (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, that act as ligands for one or more of the melanocortin receptors, the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to pharmaceutical compositions useful therefore comprising said peptides.... Agent: Alan F. Feeney Biomeasure, Incorporated

20090232839 - Melanoma associated peptide analogues and vaccines against melanoma: The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention... Agent: Leydig, Voit & Mayer, Ltd.

20090232840 - Vaccines against escherichia coli o157 infection: e

20090232842 - Hpv vaccine comprising peptides from host cell proteins: The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host... Agent: King & Schickli, PLLC

20090232841 - Optimzed vaccines to provide protection against ebola and other viruses: The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity... Agent: Knobbe, Martens, Olson & Bear, LLP

20090232843 - Identifying and predicting influenza variants and uses thereof: The instant invention provides methods for determining, predicting and characterizing the genetic variability of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090232844 - Immunopotentiating compounds: The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).... Agent: Novartis Vaccines And Diagnostics Inc.

20090232845 - Newcastle disease virus monoclonal antibodies: Anti-peptide monoclonal antibodies (MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1) and END virus (ENDV). Exotic Newcastle Disease is a contagious and fatal viral disease of birds and poultry. The present invention provides for diagnostic detection... Agent: Usda, Ars, Ott

20090232846 - Pestivirus mutant for use in a vaccine: The present invention comprises new pestivirus mutants, characterized in that the mutants are based on a cp strain of the virus wherein part of the gene sequence encoding the Npro region is deleted, except that the deleted part does not encompass the coding sequence for the N-terminal twelve amino acids... Agent: Intervet/schering-plough Animal Health Attn: Jill Corcoran

20090232847 - Immunogenic compositions: The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines that encode the HCV Core protein and a polynucleotide sequence that encodes at least... Agent: Glaxosmithkline Corporate Intellectual Property- Uw2220

20090232848 - Methods for cultivating lawsonia intracellularis: This invention relates to methods for cultivating Lawsonia intracellularis. In particular, the present invention provides improved methods for cultivating Lawsonia intracellularis by employing reducing agents other than molecular hydrogen; or alternatively, by employing a combination of one or more reducing agents with molecular hydrogen. This invention also relates to vaccines... Agent: Pharmacia & Upjohn

20090232849 - Methods and compositions for the treatment of cancer: Compositions and a method for sensitizing a cancer for treatment by cytotoxic therapy is disclosed. The method includes the step of administering to the cancerous tissue or cells a pharmaceutical composition containing a Botulinum toxin, BT.... Agent: Knobbe Martens Olson & Bear LLP

20090232851 - Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative: The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous,... Agent: Hunton & Williams LLP Intellectual Property Department

20090232850 - Therapeutic treatments using botulinum neurotoxin: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by... Agent: Allergan, Inc.

20090232852 - Use of outer membrane protein a (ompa) in treatment/prevention/diagnosis of infections caused by klebsiella pneumoniae and other gram-negative bacteria: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also... Agent: Wpat, PC Intellectual Property Attorneys

20090232853 - Treatment of laminitis: The present invention provides a composition comprising one or more of a matrix metalloprotease inhibitor, a de-carboxylase inhibitor, a fructanase enzyme and/or a flavonoid for use in the prevention of laminitis... Agent: Fulbright & Jaworski, LLP

20090232854 - Uses of bispecific antibody coated dendritic cells pulsed with antigens and gm-csf in immune regulation: GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells... Agent: Barnes & Thornburg LLP

20090232859 - Cosmetic: -

20090232857 - Method and process for the production of multi-coated recognitive and releasing systems: The present invention includes compositions, methods, systems for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles.... Agent: Chalker Flores, LLP

20090232858 - Method and process for the production of multi-coated recognitive and releasing systems: The present invention includes compositions, methods, systems for the controlled delivery of an active agent in a tablet polymer comprising two or more layers, wherein each of the two or more layers comprises at least one active agent and at least one molecular recognition polymer, wherein the two or more... Agent: Chalker Flores, LLP

20090232855 - Percutaneous controlled releasing material using nano-sized polymer particles and external application agent containing the same: A percutaneous releasing material and agent having characteristics that include a high stability of an active agent in the formulation, a high topical absorption rate, decreased irritation on the skin, and an increased tactile comfort. The percutaneous releasing material incorporates an external application agent composition that is prepared by using... Agent: Sughrue Mion, PLLC

20090232856 - Stable three-phased emulsions: Disclosed is a three-phase emulsion comprising an aqueous-gel outer phase; and a water-in-oil inner phase, wherein the emulsion is stable. The aqueous-gel outer phase can include 10% to 50% by weight of the total weight of the emulsion. This phase can also include 70% to 95% by weight of water... Agent: Fulbright & Jaworski L.L.P.

20090232860 - Colloidal metal-containing skin sanitizer: The present disclosure is drawn to disinfectant hand sanitizing compositions. In one embodiment, a hand sanitizing compositions can include from 10 to 1500 ppm colloidal silver, from 0.01 wt % to 30 wt % alcohol, at least 70 wt % water, and a thickening agent. The hand sanitizers can provide... Agent: Thorpe North & Western, LLP.

20090232861 - Extraction and sequestration of carbon dioxide: The present disclosure provides a method and apparatus for extracting carbon dioxide (CO2) from a fluid stream and for delivering that extracted CO2 to controlled environments for utilization by a secondary process. Various extraction and delivery methods are disclosed specific to certain secondary uses, included the attraction of CO2-sensitive insects,... Agent: Hayes Soloway P.C.

20090232862 - Insect screening sheet: Described is an insect screening sheet having an insect-repellent layer (10) in which the insect-repellent layer (10) has a three-dimensional surface structure which comprises a regularly periodically and/or statistically distributed coarse structure (12g) and/or nanostructure (12n),... Agent: Charles R Hoffmann Hoffmann & Baron

20090232863 - Biodegradable carbon diazeniumdiolate based nitric oxide donating polymers: Disclosed herein are implantable medical devices coated with or comprising bioabsorbable carbon-based nitric oxide-donating polymers that upon exposure to physiological environments donate nitric oxide (NO).... Agent: Medtronic Vascular, Inc.IPLegal Department

20090232865 - End-capped poly(ester amide) copolymers: This invention relates to poly(ester amide)s (PEAs) comprising inactivated terminal amino and carboxyl groups, methods of synthesizing the inactivated PEAs and uses for them in the treatment of vascular diseases.... Agent: Squire, Sanders & Dempsey LLP

20090232864 - Method for applying a bioactive, tissue-compatible layer onto shaped articles and the use of such shaped articles: A method for applying a bioactive, tissue-compatible layer onto a shaped article includes providing, as a target material, a bioactive glass ceramic having a S53P4 composition, cleaning a shaped article and activating a surface of the shaped article with ions. The Shaped article is exposed to a bioactive glass ceramic... Agent: Darby & Darby P.C.

20090232870 - Apparatus and method of retaining and releasing molecules from nanostructures by an external stimulus: An apparatus and method for using nanostructures, such as nanopores, nanofibers, nanowells, or nanocones as carriers for drugs, biomarkers and/or biomolecules. The apparatus and method for use on implant surfaces to retain and release drugs, biomarkers and/or biomolecules on command by an external stimulus.... Agent: Rockey, Depke & Lyons, LLC

20090232869 - Filamentous embolization device with expansible elements: An embolization device for occluding a body cavity includes one or more elongated, expansible, hydrophilic embolizing elements non-releasably carried along the length of an elongated filamentous carrier that is preferably made of a very thin, highly flexible filament or microcoil of nickel/titanium alloy. At least one expansile embolizing element is... Agent: Inskeep Intellectual Property Group, Inc

20090232867 - Modified conductive surfaces having active substances attached thereto: Novel processes for coating metal surfaces and/or for attaching active substances to metal surfaces, objects having coated metal surfaces and/or active substances attached thereto and uses thereof in the preparation of implantable devices are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090232868 - Nitric oxide releasing polymer composition: Disclosed herein are biocompatible carbon-based nitric oxide (NO) donating polymers suitable for forming and coating medical devices. These polymers have acrylate backbones and are comprised of substantially hydrophobic monomers. The NO donating polymers are carbon based wherein the diazeniumdiolate group is attached to the acetate group on an acetate based... Agent: Medtronic Vascular, Inc.IPLegal Department

20090232866 - Oligopeptides as coating material for medical products: The present invention relates to a pharmaceutical composition comprising a caspase inhibitor and/or a compound of the general formula R-Lys-X, methods for coating medical products using said caspase inhibitors and/or said compounds of general formula R-Lys-X and medical products coated with said caspase inhibitors and/or said compounds of general formula... Agent: Amin & Turocy, LLP

20090232871 - Biocompatible polymers and co-polymers, and uses thereof: wherein: X is —NH(CH2)4—, —O—C6H4—CH2—, —OCH2—, —O—CH(CH3)—, —S—CH2—, —O-proline, and R is H or CH3; and wherein the polymer further includes a free radical initiator and, optionally, a cross-linking agent having a plurality of polymerizable ethylenically unsaturated groups. The invention further concerns various highly biocompatible, cross-linked co-polymers comprising one or... Agent: Richard Voellmy

20090232872 - Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the... Agent: Perkins Coie LLP

20090232874 - Fibrous membrane for biomedical application based on poly(ester-amide)s: Electrospun biodegradable poly(ester-amide) fabric is especially suitable as a scaffold for tissue engineering and to incorporate drug for burn or wound healing treatment to accelerate healing, or to prevent tissue adhesion after surgery.... Agent: Bacon & Thomas, PLLC

20090232873 - Personal care composition in the form of an article: Personal care compositions, especially those personal care compositions in the form of an article that is a porous, dissolvable solid structure.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090232875 - Cartilaginiform and osteochondral substitute comprising a multilayer structure and use thereof: The present invention relates to a multilayer structure (1) including a first upper layer (2) consisting of an organic matrix including collagen and at least a lower layer (3, 4, . . . 10) consisting of a composite matrix including hydroxylapatite and collagen. Furthermore, the present invention relates to a... Agent: Pearne & Gordon LLP

20090232878 - Artificial skin substitute: The vacuum-pulled holes provide a range of porosities to ensure minimum fluid accumulation beneath the skin substitute without wound desiccation. The range of hole diameters preferred in the present invention is 0.75 mm to 1.05 mm and at holes centered at ¼″-⅓″. Providing a structure that has better acute adherence... Agent: Steven W. Webb

20090232877 - Method and composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding: A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent... Agent: Dinesh Agarwal, P.C.

20090232876 - Method and composition for in situ formation of an artificial blockage to control bleeding: A composition for in situ formation of an artificial blockage to control bleeding includes a suitable amount of a polymer-forming component, a suitable amount of a crosslinking agent, hydrogen peroxide, and a decomposing agent for hydrogen peroxide. The decomposing agent includes exogenous or endogenous catalase, or both.... Agent: Dinesh Agarwal, P.C.

20090232879 - Thyromimetics for the treatment of fatty liver diseases: The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.... Agent: Arnold & Porter LLP (23032)

20090232880 - Analogue compounds of archaebacterial membrane lipids and liposomal compounds integrating such compounds: The invention relates to a compound of general formula (I): where =0 or 1, Z=O, S or CH1-2, R1 and R2 independently=OH or OY, where Y=a protecting group, OR3, where R3=a monosaccharide or disaccharide group, A1-CH2—N+(CH3)3, X−, where X=halogen, A1=an amide (NHC(O)) or ester (OC(O)) bond, OPO(OM)2, where M=an alkali... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090232884 - Composition and method for treatment of the side-effects associated with administration of cancer chemotherapeutic agents: A composition and method for the treatment of the side-effects associated with the administration of cancer chemotherapeutic agents involves the oral ingestion of cationic liposomes containing the substrates orotate, UMP and AMP. The cationic liposomes bind to the cells lining the mucosa of the intestinal tract and then the contents... Agent: Strasburger & Price, LLP

20090232881 - Enhanced delivery of skin benefit agents: Pro-vesicles for enhanced delivery of skin benefit agents through formation of vesicular phases in the presence of water in topically applied cosmetic products, said pro-vesicles comprising: (i) the benefit agent to be delivered; (ii) a phospholipid; (iii) a mono-, di- or tri-ester of glycerol; (iv) a straight or branched chain... Agent: Unilever Patent Group

20090232883 - Method of separating vesicle, process for producing medicinal preparation, and method of evaluation: A method of separating vesicles whose membrane has been modified with a hydrophilic polymer (polyethylene glycol, etc.). In the method, vesicles (liposome, etc.) differing in the degree of membrane modification are separated by ion-exchange chromatography using a concentration gradient in which the ionic intensity of an eluent is changed with... Agent: Buchanan, Ingersoll & Rooney PC

20090232882 - Peptide based inhibition of capcna interaction in cancer: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also... Agent: Barnes & Thornburg LLP

20090232885 - Drug delivery systems comprising weakly basic drugs and organic acids: The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble drug and a pharmaceutically... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090232886 - Oral dosage combination pharmaceutical packaging: Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a... Agent: Hayes Soloway P.C.

20090232887 - Pharmaceutical composition having reduced abuse potential: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090232888 - Sustained delivery of antibiotics: The present invention is directed to compositions for the sustained delivery of an antibiotic, for example vancomycin, to achieve desirable release profiles. This application is also directed to methods of using the compositions and processes for manufacturing the compositions.... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090232889 - Crystalline salts of quinoline compounds and methods for preparing them: e

20090232890 - Compositions and methods for distraction osteogenesis: The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone... Agent: Morrison & Foerster LLP

20090232891 - Cell transport compositions and uses thereof: Compositions and methods have been developed for transporting compounds across membranes with little or no toxicity and, when targeted through the appropriate routes of administration (i.e., lung, gastrointestinal (GI) tract), little or no immune stimulation. The compositions can mediate cellular delivery of compounds that would otherwise not enter cells and... Agent: K&l Gates LLP

20090232892 - Cellooligosaccharide-containing composition: Disclosed is a cellooligosaccharide composition comprising, as the main ingredient, at least one cellooligosaccharide selected from the group consisting of cellobiose, cellotriose, cellotetraose, cellopentaose and cellohexaose, which is in the powdery form having an average L/D value of 3.0 or lower, a bulk density of 0.80 g/mL or lower and... Agent: Morgan Lewis & Bockius LLP

20090232893 - Mir-143 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-143, using miR-143 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090232895 - Procedure and devices for the controlled obtaining of dry saline aerosols with therapeutic effect: The patent refers to a procedure and devices for the generation of dry aerosols, continuously, by mechanic self-erosion, by average stirring in air or air-oxygen feed, of some crystals with special structure obtained by controlled crystallization processes. There can be also used other salts known to have physiological effects or... Agent: John Alumit

20090232894 - Process for stabilizing an adjuvant containing vaccine composition: The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090232897 - Pharmaceutical compositions comprising conjugated estrogens: Pre-mix compositions containing conjugated estrogens and a pharmaceutical carrier, and pharmaceutical formulations containing a pre-mix composition. Further, the invention includes processes for preparing the premix compositions and pharmaceutical formulations containing pre-mix compositions.... Agent: Dr. Reddy''s Laboratories, Inc.

20090232896 - Use of magnesium stearate dihydrate for lubrication of solid pharmaceutical compositions: The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of bioactive formulations including pharmaceutical compositions.... Agent: Mallinckrodt Inc.

20090232898 - Pharmaceutical compositions useful in the treatment of migraine: There is provided pharmaceutical compositions for the treatment of migraine comprising a pharmacologically-effective amount of a triptan or an ergot, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active... Agent: Morgan Lewis & Bockius LLP

20090232899 - Mucoadhesive nanocomposite delivery system: A nanocomposite delivery system uses chitosan as a mucoadhesive material encapsulated in a surface modified network of colloidal nanoporous nanoparticles, such as silica, or other colloid-forming materials, especially metal oxides. Drug delivery systems may be provided by binding a drug to the chitosan/silica nanocomposite, typically by adding a drug or... Agent: Jones Day

20090232900 - Nano-micellar preparation of anthracylcline antitumor antibiotics encapsulated by the phosphatide derivatized with polyethylene glycol: The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline antitumor antibiotics, a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar... Agent: Knobbe Martens Olson & Bear LLP

20090232901 - Polymeric microspheres: The invention features core-shell microsphere compositions, hollow polymeric microspheres, and methods for making the microspheres. The microspheres are characterized as having a polymeric shell with consistent shell thickness.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090232903 - Biocide compositions: Compositions and methods that yield chlorine dioxide upon mixing with an aqueous solution.... Agent: Manelli Denison & Selter

20090232902 - Nanometer mesoporous silica-based xerogel styptic material and its preparing process and application: The invention disclosed a novel mesoporous silica-based xerogel and its use in hemorrhage control. The mesoporous silica-based xerogel material has tunable mesopores (1-50 nm), high specific surface area (100-1400 m2/g), macroscopical morphology (powder, film, disc, column, etc.) and adjustable compositions (SiO2, CaO and P2O5, etc.) as well as good biodegradation.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090232904 - Homeopathic skin care compositions and uses thereof: The subject invention provides unique and advantageous compositions containing Argentum metallicum (homeopathic silver) for use in topical skin care. In one embodiment, the subject invention provides a gel formulation having an advantageous silver hydrosol component in addition to Argentum metallicum. In preferred embodiments of the composition of the subject invention,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090232905 - Essential oils based cleaning and disinfecting compositions: Cleaning and disinfecting compositions for cleaning, disinfecting and sanitizing inanimate and animate surfaces are provided. The cleaning and disinfecting compositions contain thyme oil or thyme oil and origanum oil, a salt of a transition metal, sodium dioctyl sulfosuccinate and water. The cleaning and disinfecting compositions are surprisingly stable and as... Agent: Townsend And Townsend And Crew, LLP

20090232907 - Compositions and methods for treatment of esophageal cancer: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast... Agent: Davidson, Davidson & Kappel, LLC

20090232906 - Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions: The present invention discloses and claims: (i) compositions, methods, and kits which lead to an increase in patient survival time in cancer patients receiving chemotherapy; (ii) compositions and methods which cause cytotoxic or apoptotic potentiation of the anti-cancer activity of chemotherapeutic agents; (iii) compositions and methods for maintaining or stimulating... Agent: Scott A. Whitaker, Ph.d., J.d. Senior Intellectual Property Counsel

20090232908 - Stable aqueous solution containing sodium pyruvate, and the preparation and use thereof: A stable aqueous solution of sodium pyruvate for medical use, which contains mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H+ which leads to pH 3.0-6.0 or NaCl which provides at least 20 mM Na+.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090232909 - Method for determining physiological effects of hemoglobin: NO preferentially binds to the minor population of the hemoglobin's vacant hemes in a cooperative manner, nitrosylates hemoglobin thiols, or reacts with liberated superoxide in solution. The distribution of minor forms of hemoglobin can be tested and the results can be used to predict whether a composition of hemoglobin will... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090232910 - Biomarkers and therapeutics targets for cognitive decline: Enrichment of S and Z polymorphisms of alpha-1-antitrypsin (AAT) in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and... Agent: Banner & Witcoff, Ltd.

20090232913 - Composition for the control of cholesterol levels: The present invention relates to a composition used to control cholesterol levels. In particular, the present invention relates to a method for the treatment or prevention of disorders or diseases mediated by hyperlipidemia, said method comprising administering to a mammalian subject in need thereof an effective amount of a composition... Agent: Frommer Lawrence & Haug

20090232912 - Method for preparing extract for the prevention and treatment of hyperlipidemia and obesity from the extract of aster spathulifolius aerial part and composition containing the same: The present invention relates to a method for preparing an extract of the aerial part of Aster spathulifolius effective in preventing and treating hyperlipidemia and obesity and a composition comprising the extract. Since most of salt which is originally abundant in Aster spathulifolius, phenolic compounds which are unstable and susceptible... Agent: Sughrue Mion, PLLC

20090232911 - Use of sericin for improving feeling in use of denture: The purpose is to prevent, ameliorate or relieve various conditions induced in the dried oral cavity or to improve the stability of a denture during use. A solution for treating a denture or a denture stabilizer comprising sericin can be used.... Agent: Dilworth & Barrese, LLP

20090232914 - Pharmaceutical composition for treating depression and method for preparation thereof: A pharmaceutical composition for treating depression and method for preparation thereof is provided. The pharmaceutical composition includes Radix Ginseng, Radix Glycyrrhizae, and/or their aqueous or alcoholic extract. Fructus Jujubae or their aqueous or alcoholic extract can also be included in the pharmaceutical composition.... Agent: Volpe And Koenig, P.C.

20090232915 - Mixtures with a collagen synthesis boosting action: The invention relates to synergistically active, ternary mixtures which boost collagen synthesis and to the uses thereof, in particular for slowing down skin ageing and for wound healing of damaged skin. The invention furthermore relates to the use of the ternary mixtures according to the invention for treating the oral... Agent: Connolly Bove Lodge & Hutz LLP

20090232916 - Food products for diabetics: Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20090232917 - Composition for relieving subjective symptoms of fatigue: There has been a demand in the marketplace for medicines, functional foods and so on which can relieve subjective symptoms of fatigue in persons having these subjective symptoms, and enabling the persons to have productive days. That is, an object of the present invention is to provide a composition for... Agent: Darby & Darby P.C.

20090232919 - Composition comprising liquiritigenin for preventing and treating liver disease: The present invention is related to a composition comprising an extract of licorice or liquiritigenin isolated therefrom significantly decrease the blood concentration of LDH and ALT enzyme, central necrosis and inflammation in acetaminophen-induced hepato-toxicity animal model when the inventive extract or compound of the present invention was orally and intravenously... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090232918 - Compositions and methods for controlling insects: The present invention comprises compositions, methods and cell lines related to controlling insects. An embodiment of a composition comprises a plant essential oil and targets at least one receptor of insects chosen from tyramine receptor, Or83b olfactory receptor, and Or43a olfactory receptor, resulting in a change in the intracellular levels... Agent: Davis Wright Tremaine LLP - San Francisco

20090226366 - Choline: early detector of cancer: The current invention detects cancer in its early stages as proliferation measurement. This material “choline” can be tagged to several radioactive substances that can be used noninvasively to detect and monitor therapy, treatment and the management of cancer.... Agent: Furr Law Firm

20090226367 - Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer: The present invention provides combination therapy methods, formulations and kits useful for managing or treating a CA 125-related disorder or symptom thereof. In one aspect, the present invention provides methods for managing or treating a cell proliferative disorder, such as a cancer, for example, ovarian cancer, comprising administering a combination... Agent: Seed Intellectual Property Law Group PLLC

20090226368 - Androgen-receptor (ar) ligands for use in the treatment and diagnosis of ar-related pathologies: The present invention discloses novel compounds and compositions suitable for the treatment of androgen related pathologies. The invention also provides diagnostic compositions for the diagnosis or monitoring of such androgen pathologies.... Agent: The Nath Law Group

20090226369 - Stq peptides: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also... Agent: Wilson Sonsini Goodrich & Rosati

20090226371 - Fluorescent nanoparticles: The use of fluorescent nanoparticles comprising an inorganic core, a passivating layer and specific ligands having a hydrodynamic diameter of the inorganic core with the passivating layer of not more than 15 nm, preferably of not more than 10 nm, particularly preferably of not more than 5 nm, for preparing... Agent: Henry M Feiereisen, LLC Henry M Feiereisen

20090226370 - Gep, a novel chondrogenic growth factor and target in cartilage disorders: The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening... Agent: Klauber & Jackson

20090226372 - Methods and compositions related to peptides and proteins with c-terminal elements: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090226374 - Anaphylatoxins for detecting clinical conditions: Non-allergic hypersensitivity reactions can be observed in a sample of cells from a subject in response to anaphylatoxins. Accordingly, methods are provided for detecting clinical conditions such as cellular hyper-reactivity, non-allergic hypersensitivity, asthma, inflammation, chronic or acute infection, bacterial infection, viral infection, parasite infection, adverse drug reaction, organ rejection, vasculitis,... Agent: Dla Piper LLP (us)

20090226373 - Method of determining the effect of a spill on a marine environment: A method of determining the effect of a spill on a marine environment, in which physical and chemical sensors are arranged with living organisms (4, 6) fitted with instruments, at an appropriate distance and position from the object (1) which is to be monitored, wherein the response of the living... Agent: Knobbe Martens Olson & Bear LLP

20090226375 - Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof: The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090226376 - Novel mixed ligand core/shell iron oxide nanoparticles for inflammation imaging: A nanostructure includes (1) an inorganic nanoparticle core; (2) a first ligand, having a first chain length, bonded to the inorganic nanoparticle core; the first ligand having a charge; and (3) a second ligand, having a second chain length, bonded to the inorganic nanoparticle core; the second ligand is hydrophilic.... Agent: General Electric Company Global Research

20090226377 - Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors: n

20090226378 - Coded medications and methods of preparing same for identification and distinguishment: A selected substance is dissolved into a given injectable fluid medication having an initial clear visual appearance. The selected substance is selected from a group of substances which, when dissolved in the injectable fluid medication, will alter the clear appearance to produce a non-clear or altered visual appearance. The altered... Agent: J. Bruce Hoofnagle

20090226379 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20090226380 - Topical skin treating compositions: A topical composition and methods of using same for treating various skin disorders or conditions. In a particular aspect, these compositions comprise a storage-stable benzoyl peroxide-containing composition in suspension and an antibiotic or pharmaceutically acceptable salt or ester thereof in solution and a retinoid or a pharmaceutically acceptable salt thereof... Agent: The Nath Law Group

20090226382 - Hair care compositions and methods of treating hair using same: The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.... Agent: Fitzpatrick Cella Harper & Scinto

20090226381 - Method and composition for reducing the drying time of hair: The invention concerns to a method and composition for improving the drying time of hair, for example, after bathing, shampooing, swimming, and the like by impregnating it with a particular amino functional silicon derivative. In a preferred embodiment the invention concerns to hair styling compositions that are applied to dry... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090226383 - Chewing gum having improved release of chewing gum ingredients: The invention relates to chewing gum comprising at least one biodegradable polyester copolymer obtained by the polymerization of two or more cyclic esters by ring-opening, said at least one biodegradable polyester copolymer having a molecular weight of less than 150000 g/mol and said chewing gum further comprising chewing gum ingredients.... Agent: St. Onge Steward Johnston & Reens, LLC

20090226384 - Antimicrobial composition containing triclosan and at least one functionalized hydrocarbon: The invention disclosed in this application relates to a synergistic antimicrobial composition containing triclosan and at least one functionalized hydrocarbon and/or mixtures containing such functionalized hydrocarbons. The ratio of Triclosan to that of the functionalized hydrocarbon and/or mixtures containing such functionalized hydrocarbons may be in the range of 1:5-1:100. The... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090226385 - Method for enhancing dispersion of inorganic compounds using silicone-containing esters and compositions formed therefrom: A cosmetic composition comprising: (a) an aqueous and/or oil phase comprising: (i) water, and (ii) at least one cosmetically active ingredient; (b) a coupling agent; and (c) an oil phase comprising: (i) an isoparaffin solvent, and (ii) a silicone-containing solvent having the formula:... Agent: Exxonmobil Chemical Company

20090226386 - Self-tanning composition: Self-tanning compositions are provided. They comprise a self-tanning agent such as 1,3-dihydroxyacetone, optionally at least one dye, a modified starch gelling agent, and optionally a branched polysaccharide gelling agent. The compositions may be in the form of emulsions or foams and provide excellent stability of the self-tanning agent.... Agent: Philip S. Johnson Johnson & Johnson

20090226388 - Skin whitening method using pleurotus nebrodensis: The present invention provides an antioxidant and a whitening agent having high safety, and a external preparation for skin using the same. The antioxidant and whitening agent comprise, as an effective component, one or more extracts from Basidiomycetes selected from the group consisting of Pleurotus abalonus, Pholiota squarrosa, Onnia orientalis,... Agent: Rankin, Hill & Clark LLP

20090226387 - Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation: The present invention describes materials and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.... Agent: Marshall, Gerstein & Borun LLP

20090226389 - Oxidant for hair treatment: The invention relates to an aqueous oxidant for hair treatment which comprises the following, by weight based on the total weight of the oxidant: 1) 3 to 15% of a peroxide and/or a persulfate; 2) 0.05 to 2% of at least one perfume containing: •5 to 100%, by weight based... Agent: Sughrue-265550

20090226390 - Hair styling composition: Hair styling composition comprising a first polymeric quaternary ammonium salt, a second polymeric quaternary ammonium salt and a cosmetically acceptable carrier. This composition is suitable for achieving a hair style having long-lasting hold with high-setting properties.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090226391 - Hemostatic sponge and method of manufacture: A method of making a wound dressing comprises dissolving at least one hemostatic agent in at least one solvent to form a solution. The method continues by freeze drying the solution to form a sponge. The method further comprises compressing the sponge, wherein the sponge is subjected to a vapor... Agent: Baker Botts L.L.P.

20090226392 - Phosphate-binding polymers for oral administration: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.... Agent: Jones Day

20090226393 - Polymer paclitaxel conjugates and methods for treating cancer: Pharmaceutical compositions comprising a PGGA-PTX conjugate are prepared. The pharmaceutical compositions are used to treat a variety of cancers, such as lung cancer, skin cancer, kidney cancer, liver cancer and spleen cancer.... Agent: Knobbe Martens Olson & Bear LLP

20090226394 - Biocidal coatings: in which N is a primary, secondary, tertiary or quaternary nitrogen atom, or a polyvinylamine which comprises at least 95% by weight of ethylenically unsaturated compounds capable of free radical polymerization and having a primary, secondary, tertiary or quaternary amino group in polymerized form, and the polymer comprises from 0.1... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090226395 - Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090226397 - Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination: Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).... Agent: Morris Manning Martin LLP

20090226396 - Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation: The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line H358, which are stimulated by receptor ligands to induce EMT, or which have been... Agent: Osi Pharmaceuticals, Inc.

20090226398 - Anti-viral compounds, compositions, and methods of use: Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.... Agent: Glaxosmithkline C/o Foley & Lardner LLP

20090226400 - Continuous delivery methods for treating hepatitis virus infection: The present invention provides methods of treating hepatitis virus infection. The methods generally involve administering an IFN-x by continuous delivery. Continuous delivery of IFN-x provides for a serum profile of IFN-x such that a sustained viral response is achieved.... Agent: Roger Brauer

20090226399 - Medicaments comprising gene recombinant antibody against ganglioside gd3: An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone,... Agent: Nixon & Vanderhye, PC

20090226404 - Methods for generating antigen-specific effector t cells: The invention relates to T cells transiently transfected with RNA, especially RNA encoding a T cell receptor and/or FoxP3, and to methods of transfecting T cells with RNA by electroporation. Compositions of the invention include an effector T cell transiently transfected with RNA encoding a T cell receptor (TCR) specific... Agent: Merix Bioscience, Inc.

20090226403 - Olfactory and pheromones g-protein coupled receptors: The present invention is related to an olfactory or pheromone G-protein coupled receptor having an amino acid sequence which presents 95% sequence identity with the sequence SEQ ID NO. 1.... Agent: Edwards Angell Palmer & Dodge LLP

20090226405 - Compositions and methods to treat cancer with cupredoxins and cpg rich dna: The present invention relates to compositions comprising CpG rich DNA from Pseudomonas aeruginosa. The compositions optionally comprise a cupredoxin. The present invention includes specific CpG DNAs from Pseudomonas aeruginosa that are useful for treating cancer and other conditions in patients. These compositions are optionally in a pharmaceutically acceptable carrier and... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090226402 - Compositions and methods of vascular injury repair: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.... Agent: Greenberg Traurig, LLP

20090226401 - Methods and compositions for the treatment of parkinson's disease: The invention features methods and kits for treating or inhibiting the development of Parkinson's Disease by administering 7-chloro-4-aminoquinoline compounds, e.g., amodiaquine or glafenine. Stem cells are also useful in the methods of the invention and may be administered separately from or together with 7-chloro-4-aminoquinoline compounds. The invention further features methods... Agent: Clark & Elbing LLP

20090226406 - Modulation of stem and progenitor cell differentiation, assays, and uses thereof: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to... Agent: Jones Day

20090226408 - Anti-fatigue composition: e

20090226409 - Pharmaceutical compositions comprising sods and prolamine based peptide fragments: The present invention relates to pharmaceutical compositions adapted for pharmaceutical administration comprising at least one superoxide dismutase and at least one prolamine based peptide fragment. The invention also relates to certain superoxide dismutases and prolamine based peptide fragments... Agent: Hoffmann & Baron, LLP

20090226410 - Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots: It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090226411 - Chemical derivatives and their application as antitelomerase agents: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090226412 - Agent for reduction of bleeding in cerebrovascular disorder: The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that... Agent: Sughrue-265550

20090226414 - Method for detecting infectious parvovirus in pharmaceutical preparations: The present invention provides methods for detecting viral infectivity and content in an enzyme preparation. In certain embodiments, the invention relates to methods for producing a pharmaceutical pancreatic enzyme composition. In additional embodiments, the invention relates to detecting infectious porcine parvovirus (PPV) and determining PPV content in pancreatic enzyme preparations... Agent: Darby & Darby P.C.

20090226413 - Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots: It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090226415 - Modified tridegins, production and use thereof as transglutaminase inhibitors: The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids—Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or... Agent: Clark & Elbing LLP

20090226407 - Methods of treating vascular diseases characterized by nitric oxide insufficiency: The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor,... Agent: Wilmerhale/nitromed

20090226422 - Chemical inhibitors of inhibitors of differentiation: The present invention provides identification of inhibitors of inhibitors of differentiation (Id) for use in the treatment and prevention of diseases in mammals. The inhibitors of Id are effective alone in the treatment of a variety of cellular proliferative disorders including, but not limited to, diseases such as cancer, arthritis,... Agent: Jeffrey J. King, Esq. Black Lowe & Graham PLLC

20090226425 - Diagnostics and therapeutics for glaucoma: Methods and compositions for diagnosing and treating glaucoma are disclosed.... Agent: Kilyk & Bowersox, P.l.l.c.

20090226418 - Food products comprising probiotic micro-organisms and antibodies: The present invention relates to food products or pharmaceutical preparations comprising antibodies or antibody fragments which are active in the gut and probiotic micro-organisms independent from the antibodies or antibody fragments. In particular, the invention relates to a method for preparing food products and pharmaceutical preparations comprising the antibodies or... Agent: Morgan Lewis & Bockius LLP

20090226417 - Human b7 polypeptides: This invention relates to B7-H1.2 and Butryophilin 2/3, new members of the human B7 polypeptide family, methods of making such polypeptides, and to methods of using them to treat immunological conditions and to identify compounds that alter the activities of these human B7 polypeptides.... Agent: Immunex Corporation Law Department

20090226416 - Human g-protein chemokine receptor (ccr5) hdgnr10: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090226426 - Method for treating inflammation: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema,... Agent: Zymogenetics, Inc. Intellectual Property Department

20090226420 - Methods of determining the risk of developing coronary artery disease: The invention relates to predicting, or aiding in predicting, which individuals are at risk of developing coronary artery disease. The invention provides a method for identifying an individual who has an altered risk for developing CAD. The invention further relates to methods of reducing the likelihood that a subject will... Agent: Myers Bigel Sibley & Sajovec

20090226423 - Protein kinase c as a target for the treatment of respiratory syncytial virus: The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090226421 - Recombinant monovalent antibodies and methods for production thereof: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090226424 - Subdermal tissue remodeling using myostatin, methods and related systems: Systems and methods of tissue remodeling or altering a surface of a skin of a patient are provided. A method includes increasing myostatin activity in a target tissue. Methods can include increasing myostatin activity in a target tissue in addition to various tissue remodeling techniques, including cryogenic cooling of target... Agent: Townsend And Townsend And Crew, LLP

20090226427 - Novel pharmaceutical compositions for modulating angiogenesis: The present invention is related to a pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or... Agent: Millen, White, Zelano & Branigan, P.C.

20090226434 - Afucosylated antibodies against ccr5 and their use for the treatment of inflammatory conditions: An antibody binding to CCR5 and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is 65% or lower has improved properties in anti-inflammatory therapy.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090226428 - Anti-inflammatory dab: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.... Agent: Morrison & Foerster LLP

20090226429 - Antibodies that immunospecifically bind to trail receptors: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090226433 - Compositions and methods for the therapy and diagnosis of influenza: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090226435 - Engineered fusion molecules immunotherapy in cancer and inflammatory diseases: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules consisting of a tumor targeting moiety fused with one or more costimulatory molecules/chemokines/cytokines.... Agent: Craig A. Crandall, Apc

20090226437 - Humanized anti-beta7 antagonists and uses therefor: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090226439 - Method for treating dementia or alzheimer's disease: Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described.... Agent: Genentech, Inc.

20090226436 - Novel receptors: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.... Agent: Amgen Inc.

20090226432 - Pharmaceutical compositions with resistance to soluble cea: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second... Agent: Foley And Lardner LLP Suite 500

20090226438 - Polypeptides and antibodies: Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090226430 - Recombinant anti-cd4 antibodies for human therapy: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090226431 - Treatment of cancer and other diseases: The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3β,5α,6α-triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other diseases including hypercholesterolemia, autoimmune diseases, viral diseases (e.g., hepatitis B, hepatitis C, or HIV), and diabetes.... Agent: Clark & Elbing LLP

20090226441 - Activin receptor-like kinase-1 compositions and methods of use: Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists.... Agent: Genentech, Inc.

20090226440 - Prophylactic and/or therapeutic method for treatment of autoimmune disease: The present invention provides therapeutic and/or prophylactic method comprising administering to a subject an amount of a composition sufficient to reduce or deplete antibody producing cells and/or prevent expansion of said cells in a tissue or organ of a subject suffering from T cell mediated autoimmune disease e.g., type 1... Agent: Cooper & Dunham, LLP

20090226443 - Combination therapy with c-met and egfr antagonists: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.... Agent: Genentech, Inc.

20090226442 - Ron antibodies and uses thereof: The invention relates to antibodies which bind to RON (receptor d'origine nantais, MST1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific antibodies which inhibit RON-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific antibodies which block... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090226454 - Antibodies against a peptide epitope of apoliporotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090226447 - Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.... Agent: Amgen Inc.

20090226455 - Combination therapy with c-met and her antagonists: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.... Agent: Genentech, Inc.

20090226452 - Method for enhancing or inhibiting insulin-like growth factor-i: The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.... Agent: Myers Bigel Sibley & Sajovec

20090226446 - Method to inhibit the propagation of an undesired cell population: Disclosed is a method for inhibiting the propagation of an undesired cell population, the method comprising introducing into a cell an antagonist of Bat 3, or of a functional variant thereof, said antagonist depleting Bat 3, a functional variant thereof, in a cell of said cell population, and verifying the... Agent: Birch Stewart Kolasch & Birch

20090226450 - Novel 15571, 2465, 14266, 2882, 52871, 8203 and 16852 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have... Agent: Millennium Pharmaceuticals, Inc.

20090226448 - Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063,... Agent: Millennium Pharmaceuticals, Inc.

20090226449 - Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921, and 33751 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063,... Agent: Millennium Pharmaceuticals, Inc.

20090226451 - Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells... Agent: Millennium Pharmaceuticals, Inc.

20090226444 - Pharmaceutical antibody compositions with resistance to soluble cea: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ... Agent: Foley And Lardner LLP Suite 500

20090226445 - Plasmodium malariae and plasmodium ovale genes and uses thereof: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.... Agent: Paul D. Yasger Abbott Laboratories

20090226453 - Sphingosine 1-phosphate antagonism: Materials and Method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of... Agent: Arent Fox LLP

20090226456 - Tumor necrosis factor receptors 6 alpha & 6 beta: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides and antibodies that bind TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090226457 - Family of immunoregulators designated leukocyte immunoglobulin-like receptors (lir): A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies... Agent: Amgen Inc. Law Department

20090226458 - Screening for anti-cancer compounds using netrin-1 activity: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention... Agent: Foley And Lardner LLP Suite 500

20090226459 - Role of fgf-19 in cancer diagnosis and treatment: The present invention relates, in part, to the discovery that human FGF19 is amplified in a number of cancers, including liver and esophageal cancers, and that this amplification correlates with over-expression of this gene. In some aspects, the invention provides methods and kits for diagnosing a patient having or at... Agent: Wolf Greenfield & Sacks, P.C.

20090226460 - Compositions and methods for the treatment of disease: The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis... Agent: Alston & Bird LLP

20090226461 - Il1-beta binding antibodies and fragments thereof: An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 9, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β binding antibodies or IL-1β... Agent: K&l Gates LLP

20090226462 - Type iii secretion pathway in aeromonas salmonicida and uses therefor: Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as other diagnostic and therapeutic uses thereof.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090226463 - Novel method of modulating bone-related activity: This invention relates to modulating bone-related activity in a subject by modulating Ror molecules. The invention further relates to compositions and methods for the screening, diagnosis and development of therapies for bone-related disorders. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that... Agent: Wyeth Patent Law Group

20090226467 - De novo synthesis of bacteriochlorins: to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry,... Agent: Myers Bigel Sibley & Sajovec

20090226464 - Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is selected from the group consisting of... Agent: Merck And Co., Inc

20090226465 - Macrocyclic depsipeptide antibody-drug conjugates and methods: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab (L D)p I where one or more macrocyclic depsipeptide drug moieties (D), selected from Aplidin, Didemnin B, Kahalalide F, and analogs and derivatives therefrom, are covalently attached by a linker (L) to an antibody (Ab) which binds to... Agent: Genentech, Inc.

20090226466 - Therapeutic anti-her2 antibody fusion polypeptides: Therapeutic protein fusions comprising anti-HER2 antibody and MicB sequences are described along with methods for their production and use... Agent: Genentech, Inc.

20090226468 - Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090226470 - Compositions and methods related to mrna translational enhancer elements: Provided are mRNA translational enhancer elements (TEEs), e.g., SEQ ID NOs:1-35. Also provided are translational enhancer polynucleotides that comprise one or more of the specific TEEs exemplified herein or their variants, homologs or functional derivatives. Further provided are expression vectors comprising such TEEs or translational enhancer polynucleotides, as well as... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090226471 - Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment: The present invention provides of using multimeric MHC class II/peptide complexes. In one aspect, methods provided for identifying MHC class II-restricted immune epitopes of a predetermined polypeptide antigen. Methods for identifying an immunostimulatory epitope for a predetermined polypeptide antigen are provided. In a related aspect, methods for screening a therapeutic... Agent: Townsend And Townsend And Crew, LLP

20090226469 - Shiga toxoid chimeric proteins: A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus... Agent: Morgan Lewis & Bockius LLP

20090226474 - Antibodies as t cell receptor mimics, methods of production and uses thereof: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such... Agent: Dunlap Codding, P.C.

20090226476 - Human glycoform: The present invention relates to a composition of matter consisting of fully humanized recombinant human lactoferrin (rhLF) that is capable to elicit the immune responses with respect to disease or drug-induced immune impairment in humans.... Agent: Conley Rose, P.C. David A. Rose

20090226472 - Interleukin-4 receptors: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4... Agent: Immunex Corporation Law Department

20090226473 - Lymphocyte surface receptor that binds caml and methods of use thereof: A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for... Agent: Alston And Bird LLP St. Jude Children's Research Hospital

20090226475 - Peptide-based immunization therapy for treatment of atherosclerosis: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090226477 - Pth2 receptor selective compounds: This invention relates to a series of PTH and PTHrP analogues that selectively bind to PTH2 receptors and as such may be useful in treating abnormal CNS functions; abnormal pancreatic functions; divergence from normal mineral metabolism and homeostasis; male infertility; regulation of abnormal blood pressure; and hypothalmic disease.... Agent: Biomeasure, Incorporated

20090226478 - Early detection of flaviviruses using the ns1 glycoprotein: The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090226480 - Streptococcus uberis adhesion molecule: A polypeptide, designated as “Streptococcus uberis Adhesion Molecule” (SUAM), and fragments of SUAM, prevent internalization and adherence of Streptococcus uberis and other streptococcal pathogens to cells. The SUAM polypeptide and fragments may be used diagnostically and therapeutically. Nucleic acid sequences encoding the SUAM polypeptide and fragments are included in the... Agent: Howard Eisenberg, Esq.

20090226479 - Vaccines and their use: p

20090226481 - Compositions ameliorating a reduced diurnal activity and/or depressive symptoms: A composition having an activity of ameliorating the reduced amount of diurnal activity and/or depressive symptoms, comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid.... Agent: Drinker Biddle & Reath (dc)

20090226482 - Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same: An herbal composition comprises an extract of Radix Rehmanniae, and an extract of Poria, Ganoderma Lucidum, Semen Ziziphi Spinosae, Semen Platycladi, Radix Rehmanniae Praeparata, Radix Angelicae Sinensis, Radix Et Rhizoma Salviae Miltiorrhizae, Rhizoma Chuanxiong, Rhizoma Atractylodis Macrocephalae, Fructus Gardeniae, Cortex Moutan, Radix Bupleuri, Radix Paeoniae Alba, Rhizoma Cyperi, Pericarpium Citri... Agent: EagleIPLimited

20090226483 - Super brown cream: A topical cream for use in healing hemorrhoids, tumid veins, damaged capillaries, rectal bleeding and rectal discomfort. The cream comprises propolis that has been extracted from material formed by honeybees, such propolis is present in the cream in a predetermined amount. Olive oil is blended with such propolis in a... Agent: James Ray & Associates

20090226484 - Immunogenic lhrh compositions and methods relating thereto: The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns... Agent: Pfizer Inc Mary J Hosley

20090226485 - Recombinant porcine adenovirus vector: This invention relates to a recombinant vector including a recombinant porcine adenovirus, stably incorporating and capable of expression of at least one heterologous nucleotide sequence. The nucleotide sequence is preferably one which encodes an antigenic determinant of Hog Cholera Virus or Pseudorabies virus. The further invention relates to a method... Agent: Mcandrews Held & Malloy, Ltd

20090226487 - Avian embryo particulate biomass for the production of virus antigens: The present invention provides a biomass which comprises avian embryonic particles having a particle size of about 0.5 mm to 10.0 mm and the use thereof in a method for the production of virus antigens. Also provided is a method for the preparation of a vaccine useful for the amelioration... Agent: Wyeth Patent Law Group

20090226486 - N protein mutants of porcine reproductive and respiratory syndrome virus: The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided.... Agent: Pfizer Inc Mary J Hosley

20090226488 - Vaccine comprising an attenuated pestivirus: Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Ems in addition to the inactivation of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090226489 - Viral vaccine composition, process and methods of use: A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is... Agent: Connolly Bove Lodge & Hutz LLP

20090226490 - Use of whole bacterial cells (actinomycetales) for maternal administration to modulate offspring immune response: Use of a composition comprising a whole cell of a bacterium from a genus of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for modulating the immune response of a recipient wherein said composition is administered to a subject and said recipient is exposed to... Agent: Steptoe & Johnson LLP

20090226491 - Water-based delivery systems: The invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor.... Agent: Reed Smith LLP

20090226493 - Agglomerates of sucralose and polyols, and their use in chewing gums: The invention provides co-agglomerates of sucralose and a polyol, wherein the co-agglomerate comprises grains of polyol onto which sucralose has been dried, as well as methods for making such co-agglomerates. In general, the methods comprise contacting a dry powder of polyol with a liquid solution of sucralose in a food... Agent: Ratner Prestia

20090226492 - Use of an activated zeolite as a pharmaceutical agent for reducing toxic substances: The invention relates to the use of an activated and modified zeolite as a pharmaceutical agent for diseases of the metabolic organs, particularly the liver, kidneys and pancreas by adsorbing heavy metals such as lead and mercury and/or ammonia in the digestive tract of humans and animals and for their... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090226495 - Nanodiamond enhanced efficacy: The present invention is directed to attaching drugs and other functional groups to surfaces of nano-sized diamonds (NDs) to enhance the efficacy of drugs and other substances. The method involved enhancing the efficacy of a drug having an active site by acquiring a plurality of nanodiamond (ND) particles having a... Agent: Zale Patent Law

20090226494 - Pathogen - controlling products: An antibacterial formulation which comprises: (a) at least one water soluble copper compound able to form copper ions upon dissolution in an aqueous medium; (b) at least one water soluble ammonium agent able to form ammonium ions upon dissolution in an aqueous medium; (c) at least one water soluble acid,... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090226496 - Formulation: A product comprising microcapsules which themselves comprise (a) a polymeric shell; and (b) a core which comprises (i) a solid agrochemical dispersed in a matrix and (ii) a water-immiscible liquid characterised in that the matrix is distributed non-continuously throughout the water-immiscible liquid.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090226497 - Alcohol antimicrobial skin sanitizing compositions including cationic compatible thickeners: The present disclosure generally relates to alcohol antimicrobial skin sanitizing compositions for use in hand washing and skin sanitizing. The antimicrobial skin sanitizing composition comprises an alcohol for providing effective antimicrobial control, one or more cationic compounds for moisturizing and protecting the skin, and a compatible thickening system for thickening... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090226498 - Moisturizing hand sanitizer: The present disclosure generally relates to moisturizing hand sanitizers including alcohols that are effective in killing microorganisms while providing a moisturizing benefit to the user's skin. More particularly, the alcohol-based hand sanitizers include a high internal phase emulsion which allows moisturizers or skin protectants such as emollients and/or silicones to... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090226499 - Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same: The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene protein (TSG-6) and hyaluronan.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090226503 - Adhesion inhibiting material for vertebral/spinal operation: It is to provide a material to inhibit spine/spinal cord adhesion in the form of a sponge, a film or a suspension to be used for the purpose of assisting/accelerating the tissue healing. An adhesion inhibiting material for a spine/spinal cord surgery in the form of a sponge, a film... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090226502 - Balloon catheter devices with solvent-swellable polymer: Methods for making a balloon catheter device comprising a solvent-swellable polymer are provided. The method includes providing a balloon, wherein a wall of the balloon or a coating over the balloon comprises a polymer, wherein the polymer is swellable in an organic solvent. In certain embodiments of the invention, the... Agent: Kenyon & Kenyon LLP

20090226501 - Drug coated stent with endosome-disrupting conjugate: A stent is provided with a drug-eluting layer disposed on at least a portion of its surface, wherein the drug-eluting layer comprises an endosome-disrupting agent and a pharmaceutical agent. In an embodiment, the endosome-disrupting agent, when taken up through endocytosis into living cells, causes lysis of endosomes containing the endosome-disrupting... Agent: Kenyon & Kenyon LLP

20090226500 - Sutures and anti-scarring agents: Sutures are used in combination with anti-scarring agents to inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described for use in reducing excessive scarring, surgical adhesion, and other disorders.... Agent: Seed Intellectual Property Law Group PLLC

20090226504 - Intravascular, interstitial or intraorgan medical access device, and manufacturing method thereof, involving nitric oxide: A intravascular, interstitial or intraorgan medical device, and a manufacturing process of said medical device, is provided that allows for prevention of infection and obtainment of anti-thrombotic effect. The medical device comprises a nitric oxide (NO) eluting polymer arranged adjacent mammal tissue, such that a therapeutic dose of nitric oxide... Agent: Inskeep Intellectual Property Group, Inc

20090226505 - Nell peptide expression systems and bone formation activity of nell peptide: The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides.... Agent: Squire, Sanders & Dempsey L.L.P.

20090226506 - Patterned gradient wound dressing and methods of using same to promote wound healing: The present invention provides a wound dressing that includes a patterned gradient of immobilized growth factor molecules that promote directed migration of cells during dermal wound healing. Growth factor is immobilized on a support substrate to present a gradient pattern of increasing growth factor concentration to migrating cells. Methods of... Agent: Quarles & Brady LLP

20090226507 - Hydroxide-releasing agents as skin permeation enhancers: A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20090226509 - Composition for treatment of inflammatory disorders: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than five (5) mole percent of charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the... Agent: Traskbritt, P.C.

20090226508 - Methods and materials for immunization against cancer: Disclosed are compositions comprising embryonic stem cells. In some embodiments, the compositions include a plurality of pluripotent cells and one or more pharmaceutically acceptable carriers or excipients. Also disclosed are methods for pro-phylaxis and/or treatment of subjects using the disclosed compositions, and methods for identifying an antigen shared by a... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090226511 - Novel pharmaceutical formulation in the form of cellulose capsules suitable for benzimidazole derivatives: A filled cellulose capsule for oral administration, wherein the capsule comprises a cellulose derivative as the base and the filling comprises a therapeutically effective amount of a benzimidazole derivative but does not comprise a lower-substituted hydroxypropyl cellulose (13 to 16% hydroxypropoxy groups) is disclosed.... Agent: Arent Fox LLP

20090226510 - Pharmaceutical compositions of atorvastatin: A unit dosage form comprising atorvastatin or a pharmaceutically acceptable salt thereof, prepared without a granulation step, wherein the measured atorvastatin potency of said dosage form shows a relative standard deviation (RSD) for atorvastatin potency per unit dosage form of not more than about 7.8%, when said unit dosage form... Agent: Pfizer Inc. Patent Department

20090226512 - Methods and compositions for oral delivery of fts: Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090226513 - Na/k-atpase ligand: This process relates to a pharmaceutical composition of an Na-K-ATPase ligand which will stimulate Na/K-ATPase signaling in a pharmaceutically acceptable vehicle. In one embodiment, the composition may be used to treat a skin disorder. In another embodiment, the composition may be used to inhibit cardiac fibrosis.... Agent: Emch, Schaffer, Schaub & Porcello Co

20090226514 - Compressed: The present invention further relates to the use of starch for increasing the rate of release of menthol from a compressed tablet. The use of starch as a carrier for the volatile active agent has been found to not only improve its rate of release from the tablet compared to... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090226516 - Sartan compositions: The invention provides a sartan or salt thereof composition having a dissolution in acetate buffer at pH 4.0 using USP type I method basket 10 Mesh at 75 rpm, of at least 20% after 90 minutes, 50% after 160 minutes, and 70% after 240 minutes... Agent: Harness, Dickey & Pierce, P.L.C

20090226515 - Statin compositions: The present invention relates to an improved statin or salt thereof composition, especially an atorvastatin composition, which exhibits enhanced dissolution properties in acidic media. It comprises a statin active ingredient and an aminoalkyl methacrylate copolymer dispersed therein, such as dimethyl aminoethyl methacrylate. The invention also relates to a process for... Agent: Harness, Dickey & Pierce, P.L.C

20090226517 - Pharmaceutical formulations comprising duloxetine: A pharmaceutical formulation comprising: a core particle comprising duloxetine or its salts; a separating layer; and an enteric layer disposed over the separating layer; wherein the formulation comprises at least one amino acid, a plasticizer, or both, in at least one of the core, the separating layer, and the enteric... Agent: Dr. Reddy''s Laboratories, Inc.

20090226518 - (monitoring only) combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing... Agent: Dykema Gossett PLLC

20090226521 - Active nanoparticles and method of using: Active multifunctional nanoparticles provide significant enhancement of the efficacy of model therapeutic and gene agents due to increased diffusion and penetration through mucus and biological barriers under the influence of a magnetic field.... Agent: Mr. Edward J. Timmer

20090226519 - Hydrogel bioscaffoldings and biomedical device coatings: Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090226520 - Medical composition employing nanostructures: A composition of microscopic devices utilizable in a medical diagnostic or therapeutic procedure. Each microscopic device includes a nanostructure provided with a ligand for effectively coupling the nanostructure to a predetermined chemical or molecular site. A medical method in part comprises inserting the medical devices into a patient, attaching the... Agent: Coleman Sudol Sapone, P.C.

20090226522 - Process to minimize polymorphism: The commercial formulation of fast dispersing dosage forms (FDDF) requires substantial holding times during which large quantities of pharmaceutically active substance are formed into individual dosage units. During this holding time, pharmaceutical agents with a propensity to polymorphism in an aqueous environment may crystallize into various, and sometimes unpredictable forms.... Agent: Fitzpatrick Cella Harper & Scinto

20090226523 - Demineralized bone matrix compositions and methods: Bone matrix compositions and, more specifically, demineralized bone matrix (DBM) having increased osteoinductive capacity and methods for its production are provided. Specifically, DBM derived from cortical bone from the periosteal layer of bone are provided. Compositions comprising a disproportionate amount of DBM prepared from bone derived from the periosteal and/or... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090226526 - Nanoparticles of a heterocrystal mineral for use as a medicament and method of producing the same: The invention relates to nanoparticles obtained by destruction of minerals for use as a medicament. Such nanoparticles exhibit high intrinsic activity, anti-bacterial, anti-viral action and can also be used for treatment of cancer and for healing wounds. Preferably, rutiles, sphenes, loparites, perowskites, anatases, ilmenites, leukoxenes, ferrites and quartzites are used... Agent: Hoffmann & Baron, LLP

20090226527 - Particulate-stabilized injectable pharmacutical compositions of posaconazole: The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090226525 - Self-assembling nanoparticle drug delivery system: A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer... Agent: Goodwin Procter LLP Patent Administrator

20090226524 - Stable active compound complex of salts of o-acetylsalicylic acid with basic amino acids and glycine: The present invention relates to stable active compound complexes of salts of o-acetylsalicylic acid with basic amino acids and glycine, to a process for their preparation and to their use as medicaments.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090226528 - Encapsulated nanoparticles for nucleic acid delivery: Methods and compositions for delivering agents (e.g., gene silencing agents) and molecules to cells using yeast cell wall particles are presented herein. Embodiments of the invention are particularly useful for the delivery of nucleic acids (e.g., siRNAs) to cells.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090226529 - Granulated composition: t

20090226530 - Powdered protein compositions and methods of making same: A method for preparing a protein or peptide powder is provided that includes spray drying a solution including more than, e.g., about 50 mg/mL of a protein or peptide (e.g., an antibody or antigen binding portion thereof), and at least one excipient. Also provided are stable powdered compositions including a... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20090226532 - Controlled release compositions for interferon based on pegt/pbt block copolymers: The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of... Agent: Brinks, Hofer, Gilson & Lione

20090226531 - Methods and composition for intraocular delivery of therapeutic sirna: Biocompatible intraocular drug delivery systems include nanoparticles that encapsulate siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.... Agent: Allergan, Inc.

20090226533 - Functional milk fraction for use against dental erosion: The present invention relates to a functional milk fraction which can be used to reduce negative effects associated with the oral uptake of acidic foods and beverages, to a method of isolating said specific milk fraction and to the use of this milk fraction in compositions for oral care. The... Agent: Norris, Mclaughlin & Marcus, P.A.

20090226534 - Bone paste composition: Bone paste compositions are described, which promote bone healing and remodeling by stimulating bone marrow elements using a combination of hemopoietic agents, angiogenic agents and a bone molecular signaling material.... Agent: Polsinelli Shughart PC

20090226535 - Food intake regulator: A safe and widely-applicable food intake regulator can be provided by using at least one of a fish brain and parts thereof, which have the activity to regulate suppress food intake.... Agent: Cantor Colburn, LLP

20090226536 - Methods and materials relating to enhanced production of dopamine neurons: Induction of neuronal fate in neural stem cells or neural progenitor or precursor cells, or other stem cells, and enhancement of induction of a specific neuronal phenotype, and particularly to induction and enhancement of induction of a midbrain dopaminergic neuronal phenotype. Expressing a nuclear receptor of the Nurr1 subfamily above... Agent: Dann, Dorfman, Herrell & Skillman

20090226537 - Mixtures comprising anthranilic acid amides and antidandruff agents as cosmetic and pharmaceutical compositions for alleviating itching: d

20090226538 - Anticancer or antiviral composition: Disclosed is an anticancer or an antiviral composition comprising therapeutically effective amounts of citric acid and or zinc and L-arginine along with a pharmaceutically acceptable carrier. The anticancer composition of the present invention has a strong anticancer effect while not having harmful side effects. The antiviral compositions of the present... Agent: Lee, Hong, Degerman, Kang & Waimey

20090226539 - Treatment of ovarian cancer: Disclosed are methods of treating ovarian cancer by administering an effective amount of FTS (farnesylthiosalicylic acid), or various analogs thereof, or a pharmaceutically acceptable salt, optionally with, a platinum-based chemotherapy drug to a human diagnosed with ovarian cancer.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090226540 - Methods and compositions for treating feline hyperthyroidism: Methods for treating feline hyperthyroidism comprising (1) administering to a feline an antithyroid agent in conjunction with feeding the feline a composition comprising from about 0.1 to less than about 1 mg/kg iodine or (2) feeding the feline a composition comprising from about 0.1 to less than about 1 mg/kg... Agent: Colgate-palmolive Company

20090226541 - Methods of reducing microbial contamination: Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided.... Agent: 3m Innovative Properties Company

20090226542 - Fitness and exercise-enhancing tablet containing protein isolate: An exercise-enhancing food tablet, preferably a hard or chewable candy or mint, is disclosed for enhancing exercise and physical fitness when ingested before, during, and/or after exercise. The edible tablet includes a mixture of carbohydrate and protein, the protein portion being between 20% and 40% of the mixture by weight,... Agent: Russ Weinzimmer

20090226543 - Agent for the therapy and prophylaxis of diabetes mellitus:

20090226545 - Anti-glycation methods and compositions: The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090226546 - Compositions derived from portulaca oleracea l. and methods of using same for modulating blood glucose levels: Compositions including anti-hyperglycemic agents from Portulaca oleracea L. are provided. Also provided are methods of isolating such anti-hyperglycemic agents and methods of using same.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090226544 - Pharmaceutical compound for treating inflammation, pain, arthritis and spinitis, and proliferating osteoblastic cell and method for producing thereof: The present invention relates to a pharmaceutical composition having efficacy in the treatment of inflammation, pain, arthritis and spinitis, and the proliferation and activity of ost eoblastic cells, and a preparation method thereof. The present invention provides a pharmaceutical composition comprising pharmaceutically effective components extracted from Cibotii Rhizoma, Ledebouriellae Radix,... Agent: Gwips Peter T. Kwon

20090226547 - Dietary supplement for eye health: Nutritional supplements for eye health comprising: an anti-oxidant component; an anti-inflammatory component; and an anti-angiogenic component. The supplements inhibit development and progression of a range of retinal diseases and degenerations, particularly AMD and diabetic eye disease, diabetic retinopathy and diabetic macular edema. The supplements include tocotrienol and green tea extract.... Agent: Fish & Richardson PC

20090226548 - Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition: A method is disclosed that prevents, controls and ameliorates urinary tract infections caused by E. coli by administering a therapeutically effective amount of a human dietary supplement composition comprising a cranberry derivative or proanthocyanidin containing concentrate and D-mannose combined in a form suitable for oral consumption. The cranberry derivative or... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20090226549 - Herbal extracts and flavor systems for oral products and methods of making the same: The invention provides a method for preparing an herbal extract and a flavor system comprising an herbal extract produced by the process. The invention also provides a flavor system comprising an herbal extract comprising thymol, eugenol, carvacrol and eucalyptol. The invention further provides a flavor system comprising a thyme extract... Agent: Michael Best & Friedrich LLP

20090226550 - Organic compositions and methods of use: An organic composition comprising ginger, turmeric, cumin, fennel, cinnamon, and red pepper, preferably in a ratio of about 1:2:1:1:1:1, is disclosed. The composition is useful for treating and/or preventing certain physical ailments.... Agent: Fay Sharpe LLP

20090226551 - Pharmaceutical composition for prevention and/or treatment of bone loss: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20090226552 - Agents and methods for diagnosing osteoarthritis: This present invention discloses disease-associated molecules and assays, which are useful for diagnosing the presence or risk of developing osteoarthritis (OA) or related conditions. The invention has practical use in the early diagnosis of disease, in monitoring mammals at risk of developing OA, and in enabling better treatment and management... Agent: Greenlee Winner And Sullivan P C

20090226553 - Method and composition using irvingia gabonensis for reducing body weight: Methods and compositions using plants from the Irvingiaceae family to reduce body weight in a mammal. Methods and compositions using the Irvingia gabonensis plant to reduce lipid levels, BMI and body weight, blood pressure, triglyceride levels, total amount of fat stored in the body, cholesterol levels, salivary and pancreatic alpha-amylase... Agent: Greenberg Traurig LLP (la)

20090226554 - Method of preparing dialysed extract of fenugreek seeds which induces hypoglycemia, mediated, in part, via stimulation of insulin signaling pathway: A method of preparing dialysed aqueous extract of fenugreek seeds comprising washing the fenugreek seeds is distilled water, sterilizing the said seeds, subjecting the sterilized seeds to the step of grinding to form powder, suspending the said powder in phosphate buffered saline (PBS), subjecting the said suspension to the step... Agent: The Webb Law Firm, P.C.

20090226555 - Extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders: The present invention relates to a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives,... Agent: Sughrue Mion, PLLC

20090220415 - Diagnostic system for the detection of skin cancer: Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the... Agent: Bozicevic, Field & Francis LLP

20090220416 - Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders: The present invention provides methods, compositions and vaccines for specifically targeting immunoglobulin associated cell-surface determinants that are not shed into the blood of a host. In some cases, the immunoglobulin associated cell-surface determinants will be involved in various B-cell disorders. The methods involve administering an IACSD targeting element to a... Agent: Gottlieb Rackman & Reisman PC

20090220417 - Methods of using il-31 monoclonal antibodies to reduce inflammation: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by... Agent: Zymogenetics, Inc. Intellectual Property Department

20090220418 - Multimodal imaging using a three compartment polymer nanoparticle with cell specificity: The present invention pertains to a three compartment structured polymer nanoparticle (core-shell-corona) for multimodal imaging with specificity for cells or cellular components, thus enabling more advanced diagnostic approaches and targeted therapy on the cellular level without the use of additional biologically active materials.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090220419 - 99mtc-labeled triphenylphosphonium derivative contrasting agents and molecular probes for early detection and imaging of breast tumors: 99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood... Agent: Quarles & Brady LLP

20090220420 - Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr): The present invention provides novel tetracyclic indole compounds of Formula (I) either as in vivo imaging agents or as therapeutic agents. A method for the preparation of the in vivo imaging agent compound is also provided by the invention, as well as a precursor for use in said method. Pharmaceutical... Agent: Ge Healthcare, Inc.

20090220422 - Drug delivery material: The present invention provides a drug delivery material, which is a conjugate of 1) a drug-carrying molecular assembly, 2) a linker and 3) a substance that recognizes activated platelet, injury site of blood vessel and/or inflammatory tissue, and capable of efficiently delivering a drug to a desired site, during which... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090220421 - Method for screening mtp-inhibiting compounds: The present invention relates to a screening method for selecting active materials that inhibit microsomal triglyceride transfer protein (MTP) and to a screening kit using the said method.... Agent: Millen, White, Zelano & Branigan, P.C.

20090220423 - Method of activating a photosensitizer: The invention relates to a method of activating a photosensitizer, wherein for the photosensitizer nanoparticles of a catalyst capable of catalyzing the production of active oxygen (1) is selected, which is further subjected to irradiation by light (5). Preferably, heterocrystal minerals are used as a source of nanoparticles. Preferably, the... Agent: Hoffmann & Baron, LLP

20090220424 - Pro104 antibody compositions and methods of use: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect... Agent: Licata & Tyrrell P.C.

20090220426 - Biodegradable inverted-opal structure, method for manufacturing and using the same, and medical implant comprising the biodegradable inverted-opal structure: (Means for Solving Problems) The present invention provides a biodegradable inverted-opal structure comprising an aliphatic polyester; and a method for manufacturing a biodegradable inverted-opal structure, comprising the steps of: (1) producing a colloidal crystal from a silica particle or a polystyrene particle; (2) immersing the colloidal crystal in a solution... Agent: Lawson & Weitzen, LLP

20090220427 - Drug resistance and methods of reversing: Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to... Agent: Wolf Greenfield & Sacks, P.C.

20090220428 - Insect repellent and process for identifying other insect repellent molecules: This invention is based on the identification of the role played by the receptor mX on certain insects through the behavior evinced in the taste sensory reactions of these insects. The invention addresses the use of the modulators on the mX receptor, such as L-canavanine and/or a mix of arginine... Agent: Morgan Lewis & Bockius LLP

20090220425 - Method to quantitatively measure effect of psychotropic drugs on sensory discrimination: A method for evaluating an effect of a psychotropic compound or a treatment on a neuronal activity of an animal including determining a change in the amount of information generated by neurons in response to at least one repeatedly applied stimulus, wherein the change is caused by administering the psychotropic... Agent: Kathryn Doyle, Ph.d Drinker, Biddle & Reath LLP

20090220429 - Method and a system for assessing neurological conditions: This invention relates to a method and a system for generating a discriminatory signal for a neurological condition, where at least one probe compound that has a neurophysiologic effect is provided. Biosignal data are obtained from a subject based on biosignal measurements obtained from biosignal measuring device adapted for placement... Agent: Knobbe Martens Olson & Bear LLP

20090220431 - Magnetic resonance imaging contrast agents containing water-soluble nanoparticles of manganese oxide or manganese metal oxide: The present invention relates to a manganese-containing metal oxide nanoparticle-based magnetic resonance imaging (MRI) contrast agent, which is characterized in that: The core of it comprises 1 to 1000 nm-sized manganese-containing metal oxide nanoparticles which include MnO a (0<a<5) or MnMbOe (wherein M is at least one metal atom selected... Agent: Dickstein Shapiro LLP

20090220434 - Nanoparticles that facilitate imaging of biological tissue and methods of forming the same: Nanoparticles that facilitate imaging of biological tissue and methods for formulating the nanoparticles are provided. In order to form suitable nanoparticles for imaging, an anionic surfactant may be applied to superparamagnetic nanoparticles to form modified nanoparticles. The modified nanoparticles may be mixed with a polymer in a solvent to form... Agent: Sutherland Asbill & Brennan LLP

20090220432 - Imaging agents and methods of using same for detecting multidrug resistance in cancer: Compounds and methods of using such compounds in the imaging and detection of multidrug resistance cancer in a subject are provided. In particular, novel imaging agents are provided which are suitable for the detection and imaging of a multidrug resistance phenotype in cancer cells and/or tissues using non-invasive medical imaging... Agent: Edwards Angell Palmer & Dodge LLP

20090220433 - Novel biotinylated compositions: Novel biotinylated composition comprising a nucleic acid, e.g. siRNA, that are useful for targeting therapeutic and imaging agents to sites of infection and tumors are disclosed.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090220430 - Fluorescent imaging agents: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable... Agent: Goodwin Procter LLP Patent Administrator

20090220436 - In situ polymerization for skin treatment: Cosmetics represent a world-wide multi-billion dollar industry. The present invention provides technology for polymerizing monomers on skin in situ to produce desired skin characteristics. For example, the inventive system may be used to reduce the signs of aging or to protect the treated skin from UV light. The polymerization of... Agent: Fitzpatrick Cella Harper & Scinto

20090220435 - Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents: Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20090220438 - Chromen-4-one derivatives as self-tanning substance: The invention relates to the use of compounds of the formula (I), where R1 and R2 may be identical or different and stand for H, OH, OCH3, CH3, CH2OH or CH2OCH3, R3 stands for H or straight-chain or branched C1- to C20-alkyl groups, R4 stands for H or OR8, R5... Agent: Millen, White, Zelano & Branigan, P.C.

20090220439 - Hydroxybenzophenone derivatives: Disclosed are hydroxyphenylbenzophenone derivatives of formula (1), wherein R1 and R2 independently from each other are hydrogen; C1-C20alkenyl; C3-C10cycloalkyl; or R1 and R2 together with the linking nitrogen atom form a 5- 6-membered heterocyclic ring; R3, R4 and R5 independently from each other are C1-C4alkyl; C1-C4alkoxy; or a radical of... Agent: Joann Villamizar Ciba Corporation/patent Department

20090220437 - Modified grape seed oils: Edible oils are described which are extracted from dried fermented grape seeds isolated from a fermented grape pomace that has undergone fermentation, e.g., primary fermentation during wine making. The edible oils contain distinguishing flavor and fragrance chemicals evidenced by organoleptic evaluation and chemical analysis, in which these chemicals are substantially... Agent: Wesley B. Ames

20090220441 - Nanoparticulate uv protectant with silicon dioxide coating: The present invention relates to nanoparticulate UV protectants which are obtainable by hydrothermal treatment of a nanoparticulate metal oxide and subsequent application of a silicon dioxide coating, and to the preparation and use thereof. The present invention furthermore relates to novel compositions, in particular for topical application, which are intended,... Agent: Millen, White, Zelano & Branigan, P.C.

20090220440 - Spray composition for topical use for treating and/or preventing herpes simplex labial infections: The present invention relates to a composition for the topical treatment of labial herpes lesions. The composition is based on preparations of officinal plants, with of anti-herpes simplex virus activity, anti-inflammatory and analgesic properties, and on natural purified components that have emollient, healing and covering effects on herpes eruptions. The... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090220442 - Sunscreen composition comprising a dibenzoylmethane, an aminohydroxybenzophenone, a triazine and a triazole as uv filters: The present invention relates to a composition comprising: a) a dibenzoylmethane derivative UV-A absorbing agent, b) a hydroxybenzophenone, c) a triazine derivative, and d) a triazole derivative, and the topical use thereof in protecting mammalian skin or hair from UV radiation.... Agent: Philip S. Johnson Johnson & Johnson

20090220443 - Compositions comprising metathesized unsaturated polyol esters: Disclosed are petrolatum-like compositions that comprise metathesized unsaturated polyol esters. Also disclosed are emulsions comprising metathesized unsaturated polyol esters. The petrolatum-like compositions may be used as substitutes for petroleum-based petrolatum. The emulsions may be water-in-oil or oil-in-water emulsions and may be suitable for a variety of end uses.... Agent: Brinks Hofer Gilson & Lione

20090220444 - Antiperspirant and deodorant compositions with improved protective action: Cosmetic and dermatological antiperspirant and deodorant compositions which have an improved care effect and comprise at least one yoghurt protein and/or at least one hydrolysate of a yoghurt protein and/or at least one N—C2-C24-acyl derivative and/or at least one C2-C24 ester and/or at least one physiologically tolerated salt of these... Agent: Ratner Prestia

20090220445 - Hair care compositions and methods for increasing hair diameter and delivering additional benefits: Disclosed in a hair care composition comprising: a hair care composition comprises: A) a hair diameter increasing agent comprising: a xanthine compound; a vitamin B3 compound; and a panthenol compound; B) an additional benefit agent, such additional benefit is selected from the group consisting of hair volume-up, hair conditioning, hair... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090220448 - Hair care compositions and methods for increasing hair diameter and for immediate fuller/thicker hair appearance: Disclosed in a hair care composition comprising: (i) a deposition agent which is in a solid particulate form on the hair; (ii) an adhesive agent which adhere the deposition agent to the hair; and (iii) an carrier; wherein either or both of the deposition agent and the adhesive agent comprises... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090220446 - Method for treating hair: A method of treating one or more hair shafts, each hair shaft including a cuticle layer and a cortex enclosed in the cuticle layer is disclosed. The method comprises: selecting one or more polymers that can penetrate the hair shafts with a pore size of about 5 angstroms to about... Agent: Peter A. Dimattia Patent And Licensing Department

20090220447 - Method for treating hair damaged by color treatments: A method of treating one or more hair shafts, each hair shaft including a cuticle layer and a cortex enclosed in the cuticle layer is disclosed. The method comprises: selecting one or more polymers that can penetrate the hair shafts with a pore size of about 5 angstroms to about... Agent: Nalco Company

20090220449 - Substituted organopolysiloxanes and uses thereof: The invention relates to new compounds of Formula 1: [(O3/2)Si CH2CH2SX]a [Si(O4/2)]b[Si(O3/2V)]C wherein X is selected from CH2A,[CH2CH2NR1]pR2, CHCOX1CH2COX2,(CH2)eCO Y[(CH2)eSCH2CH2Si(O3/2)]m[CO2(CH2)eSH]n wherein A is the residue of an amino acid or derivative or salt of an amino acid of formula CHNR1R2COX3; R1 and R2 are independently selected from hydrogen, C1-20alkyl, and... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090220451 - Cyclopropyl compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20090220453 - Enhancing stem cell mobilization: This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity.... Agent: Fish & Richardson PC

20090220452 - Method of producing a modified (poly) peptide: This invention relates to a method of producing a modified (poly)peptide, said method comprising the step of modifying in an organic solvent a crown ether-bound (poly)peptide at one or more carboxylic groups by esterification or thioesterification and/or at the amino group of the N-terminal amino acid by amidation or alkylation.... Agent: Darby & Darby P.C.

20090220450 - Methods and compositions for wound healing: Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.... Agent: Duane Morris LLP - San Diego

20090220454 - Novel hydroxamates as therapeutic agents: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also... Agent: Wilson Sonsini Goodrich & Rosati

20090220455 - Pharmaceutical compositions comprising elp fusion proteins: Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090220456 - Uses of interferons with altered spatial structure: This invention provides a method for preventing or treating Severe Acute Respiratory Syndrome in a subject comprising administering to the subject an effective amount of recombinant super-compound interferon or a functional equivalent thereof. This invention provides a method for inhibiting the causative agent of Severe Acute Respiratory Syndrome comprising contacting... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090220457 - Combinations comprising hcv protease inhibitor(s) and hcv ires inhibitor(s), and methods of treatment related thereto: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of: (a) at least one HCV IRES inhibitor; and (b) at least one HCV protease inhibitor; and optionally (c) at least one other therapeutic agent; for concurrent or consecutive administration in treating or ameliorating one or more symptoms... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090220459 - Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof: The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090220458 - Pseudotyped retroviral vectors and methods of use thereof: The present invention provides nucleic acids encoding recombinant envelope proteins; and packaging cells comprising the nucleic acids, which packaging cells provide for encapsidation of recombinant retroviral vectors. The present invention provides producer cells that produce pseudotyped recombinant retroviral vectors. The present invention further provides methods of purifying pseudotyped recombinant retroviral... Agent: Uc Berkeley - Otl Bozicevic, Field & Francis LLP

20090220469 - Peptides against autoantibodies associated with glaucoma and use of these peptides: The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090220468 - Specific cd4+cd25+ regulatory t cells for haematopoietic cell transplantation and immune tolerance: A pharmaceutical composition comprising CD4+ CD25+ regulatory T cells specific for at least one minor histocompatibility antigen, and stem cells, advantageously haematopoietic, carrying at least the antigen can be used as a medicament for increasing the immune tolerance of a histocompatible host.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090220470 - Ubiquitin binding polypeptides: The invention relates to Tandem Ubiquitin Affinity Entities (TUBES) which are fusion polypeptides comprising at least two ubiquitin binding domains connected to each other by non-naturally occurring spacer regions. The TUBES are capable of binding with high affinity to ubiquitin and to ubiquitylated polypeptides and are therefore suitable for the... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090220467 - Use of type ii pneumocytes in the treatment of pulmonary diseases associated with pulmonary fibrosis: It describes the use of type II pneumocytes as inhibitory agents of fibroblast proliferation, for which reason they can be used in the preparation of a drug for the treatment of lung diseases which present with pulmonary fibrosis.... Agent: Darby & Darby P.C.

20090220471 - Solution for the biological cleaning of toothbrushes and corresponding device: A solution for the cleaning of toothbrushes consisting of a watery solution with a mixture of non-pathogenic gram-positive bacteria of the Bacillus genus, whereby the enzymatic action decomposes any food particles remaining between the hairs of a toothbrush, and a receptacle, possibly with several compartments, for the introduction of the... Agent: Cruysberghs Rudi

20090220460 - Virus strains: The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention.... Agent: Fulbright & Jaworski, LLP

20090220464 - Mesenchymal stem cells and uses therefor: Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent: Mcandrews Held & Malloy, Ltd

20090220461 - Metastasis inhibition preparations and methods: Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue... Agent: K&l Gates LLP

20090220465 - Methods and compositions for modulation of stem cell aging: Methods are described for promoting or maintaining self-renewal of a stem cell expressing or expected to express p16INK4a employing p16INK4a inhibitors. Methods are also described for increasing the amount of self-renewing stem cells in a non-infant subject, as well as for enhancing engraftment of a stem cell expressing p16INK4a. Additionally,... Agent: Ewards Angell Palmer & Dodge LLP

20090220463 - Pharmaceutical composition for treating vascular-related diseases comprising peptide: Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090220462 - Stem cells: The present invention relates, in general, to stem cells and, in particular, to a method of expanding stem cells by inhibiting aldehyde dehydrogenase (ALDH). The invention further relates to methods of identifying compounds suitable for use in effecting expansion of stem cells.... Agent: Nixon & Vanderhye, PC

20090220466 - Very small embryonic-like (vsel) stem cells and methods of isolating and using the same: The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090220473 - Adir related polymorphisms and applications thereof: The invention relates to the field of stem cell transplantations, immunotherapy and prophylaxis of neoplastic disease. Provided are peptides comprising an amino acid sequence encoded by an open reading frame as present in the nucleotide sequence of a transcript of a naturally occurring hADIR allele, wherein the amino acid sequence... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090220472 - Method for treating malignant melanoma: The present invention discloses an immunotherapeutic method for treating patients suffering from malignant melanoma, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a malignant melanoma or a metastasis arising from malignant melanoma. The present invention provides a new... Agent: Thorpe North & Western, LLP.

20090220475 - Bone repair material: e

20090220474 - Novel a-galactosidases: This invention relates to novel α-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of α3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the GaIiIi... Agent: Foley & Lardner LLP

20090220476 - Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof: Provided is a LAGLIDADG (SEQ ID NO: 50) homing endonuclease variant having mutations in two separate subdomains, each binding to a distinct part of a modified DNA target half-site, the LAGLIDADG (SEQ ID NO: 50) homing endonuclease variant being able to cleave a chimeric DNA target sequence having nucleotides bound... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090220477 - Prevention of micronutrient deficiencies associated with common disabilities in the over 50 adult: A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B2, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, calcium, magnesium, zinc, boron and chromium in one or more specified ratios. This Abstract is not intended to define the... Agent: Greenblum & Bernstein, P.L.C

20090220479 - Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090220478 - Pharmaceutical active substance: Pharmaceutical active substance for treating tumors in the area of breast tissue (breast carcinoma) while using peptide toxin, a substance that acts in an antagonistic manner thereto, and/or a penetrating substance extracted from the venom of spiders of the family Lycosa tarantula.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090220480 - Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them: The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a β-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is... Agent: Verenium Corporation Intellectual Property Department

20090220481 - Method and compositions for treating skin: A skin care composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; a method for inhibiting damage to human keratinocytes due to environmental aggressors by applying a composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least... Agent: The Estee Lauder Cos, Inc

20090220482 - Methods and compositions for delivering interleukin-1 receptor antagonist: Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to... Agent: Harness, Dickey & Pierce, P.L.C

20090220483 - Stable enzymatic preparations and methods of use thereof: The present invention relates to stable concentrated enzymatic compositions suitable for storage under ambient conditions, while maintaining their intended enzymatic activity. The invention further relate to kits comprising concentrated enzymatic compositions, methods for preparing debriding solutions from said concentrated enzymatic compositions and methods of using the diluted debriding solutions.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090220489 - Antagonist antibodies directed against calcitonin gene-related peptide and methods using same: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.... Agent: Pfizer Inc. Patent Department

20090220486 - Antibodies and uses thereof: The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using such antibody fragments thereof are also provided. The methods and compositions according to the present invention can be... Agent: Kenyon & Kenyon LLP

20090220491 - Binding agents which inhibit myostatin: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the... Agent: Amgen Inc. Law Department

20090220490 - Compositions and assays for inhibiting hcv infection: The present invention provides isolated compounds, peptides, antibodies, vaccines that inhibit one or more functional domains of HCV E2 protein from interacting with associated proteins selected from the group consisting of AP-50, HSC70, Cyclin A, and Cyclin G. Pharmaceutical compositions and method of use thereof comprising the same for inhibiting... Agent: Sutherland Asbill & Brennan LLP

20090220488 - Evaluating and treating scleroderma: The expression of a number of genes is altered in scleroderma. Therapeutic methods for treating scleroderma can include counteracting the effects of the altered gene expression profile. Further, scleroderma can be diagnosed and monitored by evaluating the expression of one or more of the altered genes.... Agent: Biogen Idec / Finnegan Henderson, LLP

20090220485 - Method for isolation of soluble polypeptides: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library... Agent: Cassan Maclean

20090220487 - Methods and compositions for inhibition of vascular permeability: The present invention relates to methods and compositions for regulating vascular permeability. The present invention relates to methods and compositions for blocking proteins and signal transduction pathways involved in increasing vascular permeability.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090220492 - Protein purification: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.... Agent: Goodwin Procter LLP

20090220484 - Rage/diaphanous interaction and related compositions and methods: This invention provides a polypeptide consisting essentially of all or a portion of the cytoplasmic domain of RAGE. This invention further provides a polypeptide consisting essentially of a portion of Diaphanous that binds to the cytoplasmic domain of RAGE. Additionally, this invention provides related nucleic acids, vectors, cells and methods.... Agent: Cooper & Dunham, LLP

20090220493 - Reagents and methods for inducing an immune response to prostate specific antigen: The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.... Agent: Ropes & Gray LLP

20090220494 - Antibodies produced in a transgenic avian: The invention includes compositions comprising novel forms of glycosylated human interferon-α.... Agent: Synageva Biopharma Corp.

20090220499 - Agents for suppressing damage to transplanted islets after islet transplantation: The present inventors investigated anti-IL-6 receptor antibodies for their effect in suppressing damage to transplanted islets after islet transplantation. As a result, they found that anti-IL-6 receptor antibodies reduced damage to transplanted islets, improved islet survival, and corrected hyperglycemia in recipients. Further, they revealed that administration of the anti-IL-6 receptor... Agent: Fish & Richardson PC

20090220500 - Agents for treating cardiopathy: The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and... Agent: Fish & Richardson PC

20090220501 - Anti-cd19 antibody, immunotoxin and treatment method: Provided is an immunotoxin including (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A... Agent: King & Spalding LLP

20090220502 - B7 family member zb7h6 and related compositions and methods: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are... Agent: Zymogenetics, Inc. Intellectual Property Department

20090220495 - Cancer related genes (prlr): This invention is in the field of cancer-associated genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of expression of a PRLR gene or protein. The invention also provides methods and molecules for upregulating or downregulating PRLR gene... Agent: Marshall, Gerstein & Borun LLP

20090220504 - Combinatorial therapy: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present... Agent: Genentech, Inc.

20090220498 - Method for discovering inhibitors of the epstein-barr virus-induced gene 3 (ebi3) and derivatives thereof for the treatment of metastasizing tumors and allergic asthma: The present invention relates to a method for identifying inhibitors of the Epstein Barr virus-induced gene 3 (EBI3), a method for producing a pharmaceutical composition, comprising an inhibitor, a respective pharmaceutical composition and a method for treating a metastasizing tumor disease or allergic asthma, comprising the administration of an effective... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090220503 - Method for treating cancers with increased ras signaling: Disclosed herein are methods for treating a subject with, or at risk for, developing a tumor which has aberrantly increased Ras signaling. The method involves obtaining a biological sample from the subject, determining whether the biological sample contains cells which have aberrantly increased Ras signaling, and administering an agent that... Agent: Ronald I. Eisenstein

20090220505 - Methods of inhibiting amyloid toxicity: The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.... Agent: Townsend And Townsend And Crew, LLP

20090220496 - Novel uses for anti-ige therapy: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with an elevated serum IgE level may benefit from the treatment methods... Agent: Mcdermott Will & Emery LLP

20090220497 - Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment: The present invention relates generally to treatment and prophylactic protocols for cellular diseases or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides compositions comprising therapeutic antibodies and hyaluronan and their use in the treatment or prophylaxis of cellular diseases and disorders.... Agent: Morrison & Foerster LLP

20090220506 - Human epo mimetic hinge core mimetibodies, compositions, methods and uses: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors,... Agent: Philip S. Johnson Johnson & Johnson

20090220507 - Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure: The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. The present invention provides the link between ERK1/2 and calcineurin and CamKII. The present invention further demonstrates that inhibitors of ERK1/2 inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene... Agent: Fulbright & Jaworski L.L.P.

20090220508 - Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and... Agent: Ropes & Gray LLP

20090220509 - Singlec-9 binding agents: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.... Agent: Ditthavong Mori & Steiner, P.C.

20090220510 - Specific binding proteins and uses thereof: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of... Agent: Paul D. Yasger Abbott Laboratories

20090220514 - Adam10 and its uses related to infection: The present invention relates to a protein, ADAM10, ADAM10 nucleic acid sequences and ADAM10 proteins encoded by these sequences that are involved in infection by one or more pathogen such as a virus, a parasite, a bacteria or a fungus or are otherwise associated with the life cycle of a... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090220512 - Genes and polypeptides relating to prostate cancers: The present application provides novel human gene ELOVL7 whose expression is markedly elevated in prostate cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of... Agent: Townsend And Townsend And Crew, LLP

20090220511 - Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities: A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their... Agent: University Of Medicine And Dentistry Of New Jersey Office Of Patents And Licensing

20090220513 - Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications: The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and... Agent: Choate, Hall & Stewart LLP

20090220515 - Treatment and prevention of renal disease: The present invention is directed to a method of treating or preventing renal disease in a subject. This method involves administering the subject an agent which inhibits FAT10 expression in the subject under conditions effective to prevent or treat renal disease. Also disclosed is a method of screening for agents... Agent: Nixon Peabody LLP - Patent Group

20090220519 - Anti-il-22ra antibodies and binding partners and methods of using in inflammation: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20090220517 - Method for producing epitomers and their uses on carrier microorganisms: The present invention relates to a method for producing carrier microorganisms, in particular bacteria, which, through targeted genetic manipulation, carry epitopes or epitomers, respectively, on their surfaces. Epitomers are antigenically effective epitopes that can be found in the polypeptide chain in multiple identical copies, and which, when expressed on the... Agent: David S. Resnick

20090220518 - Methods and compositions for treatment of graft rejection and promotion of graft survival: Embodiments herein illustrate methods of treating, reducing or preventing transplantation rejection and/or side effects associated with transplantation. Some embodiments relate to compositions and methods for inhibition of graft rejection and promotion of graft survival. Other embodiments relate to modulation of cellular activities, including graft rejection, promotion of graft survival, graft... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090220516 - Neuroprotection of retinal ganglion cells: This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing incidence and suppressing death in ganglion cells by manipulating the P2X7 and A3 receptors on ganglion cells, by reducing levels of ATP... Agent: Pearl Cohen Zedek Latzer, LLP

20090220520 - Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia: The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090220521 - Anti mif antibodies: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain... Agent: Baxter Healthcare Corporation

20090220522 - Detoxified endotoxin vaccine and adjuvant and uses thereof: The present invention describes a detoxified Gram negative J5 core lipopolysaccharide/group B meningococcal outer membrane protein complex vaccine given in conjunction with CpG 7909 adjuvant. This vaccine composition can be used for either active or passive immunization of mammals for the prevention or treatment of sepsis and infection with Gram... Agent: Benjamin Aaron Adler Adler & Associateds

20090220523 - Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions: The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090220524 - Therapeutic agents for alzheimer's disease and cancer: e

20090220525 - Novel bacterium and vaccine: The present invention relates to a novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new, deadly, disease in fish, to a microbiological culture comprising said bacterium, to a vaccine comprising said bacterium and methods for the preparation of such a vaccine, to antibodies reactive with said bacterium, to diagnostic test... Agent: Intervet/schering-plough Animal Health Attn: Jill Corcoran

20090220526 - Acute renal injury: We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and/or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected... Agent: Banner & Witcoff, Ltd.

20090220527 - Affinity optimized epha2 agonistic antibodies and methods of use thereof: The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions... Agent: Medimmune, LLC Jonathan Klein-evans

20090220528 - Stimulation of toll-like receptors on t cells: The present invention relates to compositions and methods for modulating Toll-like receptors (TLRs) for enhancing survival of activated CD4+ T cells. The enhanced survival of activated CD4+ T cells provides a means for regulating an immune response.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090220529 - Anticancer drugs conjugated to antibody via an enzyme cleavable linker: This invention relates to the field of antibody-drug conjugates, and more particularly antibody-drug conjugates that are intended for the treatment and/or diagnosis of diseases such as tumors and/or inflammatory reactions.... Agent: Hunton & Williams LLP Intellectual Property Department

20090220531 - Composition of which chief ingredient is polysaccharides having an immunoregulatory function: An object is to establish a method of preparation of novel polysaccharides from a cassis polysaccharide (CAPS), wherein the novel polysaccharides exhibit a higher immunoregulatory effect per unit amount, have a low viscosity, and can be handled readily during the method of preparation a final product. Another object is to... Agent: Jacobson Holman PLLC

20090220530 - Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response: Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and... Agent: Klarquist Sparkman, LLP

20090220532 - Agents and methods based on the use of the eda domian of fibronectin: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090220534 - Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes: The current invention provides methods for the identification of antigens and/or epitopes that are differentially displayed on TAP deficient or TAP impaired cells and are not detectably displayed on normal or TAP proficient cells. The identification and applications of these differentially presented antigens, which in this specification are referred to... Agent: Foley And Lardner LLP Suite 500

20090220533 - Novel t-helper antigenic determinant (thd) peptides: The invention relates to a chimeric peptide, which can bind to at least one allelic form of the HLA-DR molecule. The invention also relates to a pharmaceutical composition containing said peptide, as well as to the different uses of same.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090220535 - Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection: Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090220536 - Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41: This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090220537 - Vaccine delivery system: An isolated protein comprising a hepatitis B surface antigen (HBsAg) amino acid sequence, and encoding nucleic acid, are provided wherein one or more immunogenic T cell epitopes of the HBsAg are respectively substituted with one of more immunogenic T cell epitopes of a protein other than HBsAg. Typically, the T... Agent: Leydig Voit & Mayer, Ltd

20090220538 - vaccine for staphylococcal infections: The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.... Agent: Matthias Scholl

20090220539 - Recombinant mononegaviral virus vectors: The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene.... Agent: Intervet/schering-plough Animal Health Attn: Jill Corcoran

20090220540 - Helicobacter system and uses thereof: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against... Agent: K&l Gates LLP

20090220541 - Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines: A split influenza virus vaccine is adjuvanted with an oil-in-water emulsion that contains free surfactant in its aqueous phase. The free surfactant can continue to exert a “splitting effect” on the antigen, thereby disrupting any unsplit virions and/or virion aggregates that might be present.... Agent: Novartis Vaccines And Diagnostics Inc.

20090220542 - Vaccine comprised specifically of protein subunits of human immunodeficiency virus's glycoprotein 120 probe to prevent and treat an infection caused by the human immunodeficiency virus: The human immunodeficiency virus poses a significant threat to the health and well being of the world's population. Current strategies utilized to eradicate this deadly pathogen have not been effective. A vaccine comprised solely of protein subunits of the glycoprotein 120 probe as the active ingredient, can be effective in... Agent: Lane B. Scheiber

20090220545 - Adjuvant-sparing multi-dose influenza vaccination regimen: An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the... Agent: Novartis Vaccines And Diagnostics Inc.

20090220546 - Adjuvanted influenza vaccines for pediatric use: An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The... Agent: Novartis Vaccines And Diagnostics Inc.

20090220544 - Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture: An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.... Agent: Novartis Vaccines And Diagnostics Inc.

20090220543 - Expression of proteins in plants: The invention relates to a method of producing a HPV polypeptides and/or an influenza virus H5 polypeptide in a plant comprising the steps of cloning a HPV gene; and/or an influenza virus H5 gene or nucleic acid encoding their functional equivalents into a vector adapted to target components present in... Agent: Frommer Lawrence & Haug

20090220547 - Reducing interference between oil-containing adjuvants and surfactant-containing antigens: Inclusion of fatty adjuvants in vaccine compositions can cause difficulties with certain antigenic components, particularly with antigens that include a surfactant component. A method for preparing an immunogenic composition comprising an antigen and a fatty adjuvant involves purification of the antigen substantially in the absence of surfactant. Where surfactants cannot... Agent: Novartis Vaccines And Diagnostics Inc.

20090220548 - Immunogenic agents against burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia pseudomallei: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090220549 - Reagents for recombinogenic engineering and use thereof: The present invention features homologous recombination methods and systems. The methods and systems promote highly efficient homologous recombination in cells (e.g., in prokaryotic cells). The methods and systems are useful, for example, in pharmaceutical drug development, vaccine development and cloning.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090220550 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20090220551 - Concurrent chemotherapy and immunotherapy: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this... Agent: Banner & Witcoff, Ltd.

20090220553 - Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent: The application relates, in part, to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent.... Agent: Ropes & Gray LLP

20090220552 - Formulations containing pantoprazole free acid and its salts: The invention relates to new formulations and dosage units of solid crystalline pantoprazole free acid and its salts (e.g., pantoprazole sodium sesquihydrate) that are resistant to gastric juice digestion and are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, and a process for making the same... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090220554 - Transglutaminase inhibitors and methods of use thereof: Transglutaminase inhibitors and methods of use thereof are provided.... Agent: Bozicevic, Field & Francis LLP

20090220557 - Effect pigment and use thereof in cosmetics and in the food and pharmaceutical industries: The present invention relates to intensely coloured and light-stable effect pigments based on transparent, undoped SiO2 flakes, which are distinguished by the fact that they are covered with an iron-oxide layer having a thickness of 30-150 nm, and all SiO2 flakes have an identical thickness, and the thickness of the... Agent: Millen, White, Zelano & Branigan, P.C.

20090220558 - Emulsion of a liquid fluorinated oil phase in a liquid water phase: Emulsions of a liquid oil phase in a liquid water phase which comprise a) more than 50 weight percent of a hydrofluoroether, a perfluoroether or a combination thereof, based on the total weight of the emulsion, b) a surfactant, and c) water, are useful in a cosmetic formulation or a... Agent: The Dow Chemical Company

20090220556 - Nanodiamond uv protectant formulations: A cosmetic or sunscreen preparation provides transmission attenuation of ultraviolet A and ultraviolet B and ultraviolet C light when applied to human tissue to reduce exposure comprises a dispersion of an effective amount of diamond nanoparticle in a physiologically compatible medium, where the diamond nanoparticles have a size greater than... Agent: Rader Fishman & Grauer PLLC

20090220555 - Sweat-absorbing cosmetic product and method for the production thereof: The sweat-absorbing complex in the base formulation is present in the form of emulsified particles. The particles consist of a three-dimensional, water-swellable network of said at least one water-absorbing component and are at least partially covered with said at least one surface-active agent. Said at least one electrolyte is incorporated... Agent: Norris, Mclaughlin & Marcus, P.A.

20090220559 - Multifunctional solid formulations for water conditioning: Solid formulations for use in water conditioning of circulating reservoirs, processes of preparing same and methods for water conditioning utilizing same are disclosed. The solid formulations combine a sanitizer with a bath salt and/or an odoriferous substance.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090220560 - Nanosilver coated bacterial cellulose: Nanosilver coated bacterial cellulose nanofiber and a method of producing the nanosilver coated bacterial cellulose nanofiber. The nanosilver coated bacterial cellulose nanofiber is produced by preparing a suspension of bacterial cellulose fibers, oxidizing bacterial cellulose fibers; adding the thio-group to the polymer backbone; reacting the resulting product with silver proteinate... Agent: Dowell & Dowell P.C.

20090220563 - Artificial tooth medicating apparatus for controlling, regulating, sensing, and releasing medical agents into the body: An artificial tooth apparatus for dispensing medicating agents to the body through the patient's jaw bone comprising a mechanical movement and kinetic mainspring winder, a tourbillon mechanism, a electronic regulator, and a pump mechanism arranged and configured to allow any medicating agent to be dispensed from the apparatus in a... Agent: Law Offices Of Daniel L. Dawes

20090220570 - Axon regeneration with pkc inhibitors: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a... Agent: Richard Aron Osman, Ph.d. Science & Technology Law Group

20090220566 - Bioimplants for use in tissue growth: Disclosed herein is an implant for use in stimulating tissue growth. The implant comprises a body with a body core and a body surface. The body is made from a non-hydrogel polymer material. A tissue growth stimulating material is disposed within the body core or deposited onto the body surface,... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090220561 - Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same: The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and/or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics.... Agent: Morrison & Foerster LLP

20090220565 - Method for producing autonomously contracting cardiac muscle cells from adult stem cells, in particular human adult stem cells: A method for producing autonomously contractile heart muscle cells by cultivating and differentiating stem cells obtained from differentiated exocrine gland tissue of an organism is described. Various uses of the heart muscle cells, in particular in regenerative medicine, are also described.... Agent: Pearl Cohen Zedek Latzer, LLP

20090220568 - Methods for treating a stricture with a botulinum toxin: Methods of treating a urethral stricture in a patient. The methods can include the step of administering an therapeutically effective amount of a botulinum toxin directly to a urethra of the patient, for example by use of a stent from which the botulinum toxin can elute or diffuse, thereby treating... Agent: Allergan, Inc.

20090220564 - Methods of treating and preventing acute myocardial infarction: The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near... Agent: Pepper Hamilton LLP

20090220562 - Osteogenic and anti-adipogenic oxysterols: The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators.... Agent: Venable LLP

20090220569 - Prevascularized constructs for implantation to provide blood perfusion: This application discloses methods and materials for preparing functional microvascular beds in the laboratory. These prevascularized constructs can be used to vascularize engineered tissue constructs or to revascularize damaged or diseased tissues or organs following implantation. The prevascularized constructs may also deliver genetically engineered gene products to the bloodstream.... Agent: Quarles & Brady LLP

20090220567 - Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof: An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided.... Agent: Licata & Tyrrell P.C.

20090220571 - Self-expanding devices and methods therefor: Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or... Agent: Morrison & Foerster LLP

20090220572 - Injectable combination therapy for eye disorders: The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure,... Agent: Choate, Hall & Stewart LLP

20090220573 - Method, device, and system for delivery of therapeutic agents to the eye: A method, device, and system for easier, consistent, and comfortable delivery of therapeutic agents to the front of the eye.... Agent: Sharonda R. Williams Sher Garner Cahil Richter Klein & Hilbert

20090220574 - Suramin and derivatives thereof as topical microbicide and contraceptive: The present invention is directed to methods of inhibiting STDs by topically administering suramin or a derivative thereof to actual or potential sites of infection, and methods of preventing pregnancy by topically applying suramin or a derivative thereof intravaginally. Suramin compositions that include an antimicrobial agent and/or a sperm-function inhibitor... Agent: Wilmerhale/dc

20090220575 - Compositions and methods for the sustained release of beta-alanine: Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine.... Agent: K&l Gates LLP

20090220576 - Emulsion: The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.... Agent: Knobbe Martens Olson & Bear LLP

20090220577 - Moulded body for medically treating wounds: The invention relates to an absorbable and porous shaped article for the medical treatment of wounds, in particular large, deep wounds with heavy discharge, where the shaped article is in the form of a foam structure which includes a co- and/or terpolymer based on the monomers lactide, triethylene carbonate, ε-caprolactone... Agent: The Nath Law Group

20090220579 - Gelatin non-woven structures produced by a non-toxic dry solvent spinning process: e

20090220578 - Hydrogel composition and method for making the same: Disclosed is a hydrogel composition comprising water, a first crosslinked polymer, and a second crosslinked polymer, wherein the first crosslinked polymer comprises poly(ethylene oxide) and the second crosslinked polymer comprises a hydrophilic polymer other than poly(ethylene oxide), wherein the first crosslinked polymer and the second crosslinked polymer form an interpenetrating... Agent: Leydig Voit & Mayer, Ltd

20090220580 - Percutaneous absorption formulation: The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances... Agent: Oliff & Berridge, PLC

20090220584 - Amphoteric liposome formulation: The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.... Agent: Jonathan P. O'brien, Ph.d. Miller, Canfield, Paddock & Stone

20090220585 - Biological active blood serum fraction s-1-10, methods for producing it and uses thereof: The present invention relates to a method for preparing a biological active fraction of blood serum, the biological active fraction (S-1-10) and a pharmaceutical composition comprising said fraction as well as uses thereof in the treatment of various diseases and conditions, in particular seizures, cardiovascular diseases and proliferative diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090220587 - Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands: A receptor ligand is conjugated to a lipid-soluble moiety, thereby allowing effective delivery of the peptide ligand to a target cell in the form of a liposome complex. The ligand brings the liposome in proximity to the target cell, facilitating the fusion of the liposome with an endosome of the... Agent: Drinker Biddle & Reath (dc)

20090220583 - Method and composition for treating inflammatory disorders: There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.... Agent: Morgan Lewis & Bockius LLP

20090220582 - Method of cancer treatment using sirna silencing: The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.... Agent: Knobbe Martens Olson & Bear LLP

20090220581 - Methods of reducing inflammation and mucus hypersecretion: Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090220586 - Proteomimetic compounds as inhibitors of the interaction of nuclear receptor with coactivator peptides: The present invention relates to compounds, pharmaceutical compositions and methods which inhibit the binding of coactivator proteins in nuclear receptors, including estrogen receptors (alpha and/or beta), androgen receptors, thyroid receptors and peroxisome proliferators-activated receptors, among others. Compounds according to the present invention may be useful in the treatment of a... Agent: Coleman Sudol Sapone, P.C.

20090220588 - Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity: The compositions and methods of the present invention relate to the co-delivery of a molecule and a polypeptide to cells to improve the therapeutic efficacy of the molecules. In one embodiment of the invention, the invention may improve delivery of growth factors by co-delivering these growth factors with their receptors... Agent: K&l Gates LLP

20090220589 - Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas: miRNAs that regulate human SPARC and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, ds miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA... Agent: Leydig Voit & Mayer, Ltd

20090220590 - Triple drug combinations for psychiatric patients: The mega capsule can be prescribed by any physician, and in particular those professionals in the psychiatric field. The mega capsule will be a form of medication designed for a specific patient in mind. The capsule will help the patients understand their medications better and make it easier for them... Agent: Ikemefuna Nkanginieme M.d.

20090220591 - Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic-analgesic drug and proton pump inhibotor: The present invention relates to pharmaceutical compositions in the form of fixed combination comprising non-steroidal anti-inflammatory drug or its single enantiomers or salts thereof, antipyretic-analgesic drug and proton pump inhibitor or its single enantiomers or salts thereof. The invention also relates to processes for the preparation of such compositions.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090220592 - Preparation for the treatment of tinnitus: The invention relates to the use of blueberry extract for the preparation of a therapeutic composition for oral administration for the treatment and prevention of tinnitus.... Agent: Lando & Anastasi, LLP

20090220593 - Extended release dosage forms of quetiapine: The present invention relates to multiple unit extended release dosage forms of quetiapine for oral administration, wherein each unit comprises a core containing quetiapine and one or more of pharmaceutically acceptable excipients coated with a rate-controlling coating and process for the preparation thereof.... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090220594 - tablet of paracetamol containing an encapsulated flavorant: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.... Agent: Fish & Richardson PC

20090220595 - Combination of erythropoietin glycoisoforms: This invention relates to a combination of erythropoietin glycoisoforms, wherein such glycoisoforms may include a quantity of sialic acid ranging from 4 to 10 molecules of sialic acid per molecule of erythropoietin. The combination of glycoisoforms can be used for the treatment or prevention of sepsis, and used to prepare... Agent: Ratnerprestia

20090220596 - Composition and dosage form comprising a solid or semi-solid matrix: A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid... Agent: Edwards Angell Palmer & Dodge LLP

20090220597 - Rapid release irbesartan-containing pharmaceutical composition: The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose.... Agent: Smith Patent Consulting Consulting, LLC

20090220599 - Antifungal formulation and manufacturing method thereof: A new antifungal formulation is provided. The present invention uses a sterol modified with polyethylene glycol (PEG) as a drug carrier. The drug carrier encapsulates Amphotericin B (AmB) by self-assembly to form polymeric micelles. The polymeric micelles can reduce toxicity of Amphotericin B and control release of Amphotericin B. The... Agent: Bacon & Thomas, PLLC

20090220598 - Stable oral pharmaceutical composition containing thyroid hormone receptor agonists: Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with either an enteric coating, an antioxidant, or both an enteric coating and an antioxidant. Such formulation acts to prevent the formation of undesired reaction products in vivo.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090220600 - Antimicrobial films: A film consisting of a titanium dioxide host matrix comprising silver oxide nanoparticles.... Agent: Nixon & Vanderhye, PC

20090220601 - Autologous oral grafts: The present invention provides autologous oral grafts that may be used, for example, to treat oral cavity disease characterized by inflamed or damaged oral mucosa tissue, or to treat oral caries characterized by damaged enamel, dentin, or cementum. In certain embodiments, the autologous oral grafts comprise a biocompatible matrix and... Agent: Medlen & Carroll, LLP

20090220602 - Sublimable sustained release delivery system and method of making same: The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide variety of diseases or as systems for... Agent: Pearne & Gordon LLP

20090220603 - Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics: Various methods are provided, including wound healing with reduced fibrosis, treatment of burn shock, treatment and prevention of atherosclerosis, prevention and treatment of organ transplant rejection, treatment of depression and schizophrenia and treatment of the signs of aging, such as wrinkles, each of which uses administration of a composition containing... Agent: Defillo & Associates, Inc.

20090220604 - Amino acids in micelle preparation: Formulations are formed of a diblock copolymer (X—Y) having a hydrophilic block X comprising residues of monomer x, and a hydrophobic block Y comprising residues of monomer y; an additive selected from an amino acid and an oligopeptide. Upon admixture with water, the formulations form drug delivery vehicles, preferably in... Agent: Seed Intellectual Property Law Group PLLC

20090220605 - Bone matrix compositions having nanoscale textured surfaces: Bone matrix compositions having nanoscale textured surfaces and methods for their production are provided. In some embodiments, bone matrix is prepared for implantation and retains nanoscale textured surfaces. In other embodiments, nanostructures are imparted to bone matrix wherein collagen fibrils on the surface of the bone matrix have been compromised,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090220606 - Treatment and prevention of abnormal cellular proliferation: This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of:... Agent: David S. Resnick

20090220607 - Polymeric compositions and methods of making and using thereof: Described herein are polymeric compositions having a polymer residue and a crosslinker residue, wherein the polymer residue is bonded to the crosslinker residue with a moiety formed from a cycloaddition reaction. Also, described are methods of making and using such polymeric compositions.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090220608 - Pharmaceutical composition of microspheres for preventing diabetic foot amputation: The present invention relates to a pharmaceutical composition that comprises polymeric microspheres containing epidermal growth factor (EGF) for the application, by the parenteral route, into the lower limbs of diabetic patients with cutaneous chronic ischemic ulcerative wounds. The pharmaceutical composition described herein, in contrast with the state of the art,... Agent: Hoffmann & Baron, LLP

20090220610 - suspension comprising benzimidazole carbamate and a polysorbate: This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 nm and a TWEEN-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and a... Agent: Intervet/schering-plough Animal Health Attn: Jill Corcoran

20090220609 - Process to control particle size: A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser... Agent: Moore & Van Allen PLLC

20090220611 - Microparticles with modified release of at least one active principle and oral pharmaceutical form comprising same: The invention concerns microparticulate systems with modified release of oral active principle(s). The invention aims at providing a novel pharmaceutical with time-dependent and pH-dependent release mechanism, enabling: a) the latent period preceding the release of the active principle in the stomach; b) the pH triggering the release of the active... Agent: Patton Boggs LLP

20090220613 - Controlled release delivery device comprising an organosol coat: A controlled release delivery device for controlled release of an active ingredient comprising: (i) a core particle comprising the active ingredient homogenously dispersed or dissolved therein; and (ii) an organosol polymeric coat comprising a homogenous mixture of, (a) a water soluble gel forming polymer and a water insoluble organosoluble polymer... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090220612 - Hollow-fibre-based biocompatible drug delivery device with one or more layers: A biocompatible drug delivery device in which the mean pore size in one or more layers is less than 100 μm. The device may be a hollow fibre or a membrane comprising a number of hollow fibres or a microsphere. The invention also extends to a method for preparing porous... Agent: Buchanan, Ingersoll & Rooney PC

20090220615 - Main chain acid-degradable polymers for the delivery of bioactive materials: Novel main chain acid degradable polymer backbones and drug delivery systems comprised of materials capable of delivering bioactive materials to cells for use as vaccines or other therapeutic agents are described. The polymers are synthesized using monomers that contain acid-degradable linkages cleavable under mild acidic conditions. The main chain of... Agent: United States Department Of Energy

20090220614 - Thermo-responsive block co-polymers, and use thereof: Provided are thermo-responsive polymersomes, which display cold-controlled encapsulation near the physiological temperatures, and have a PDI less than 1.2. Morphology of the thermo-responsive polymersomes is a function of the weight fraction of the hydrophilic block in the block copolymer and the number average molecular weight (Mn) of the block copolymer.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090220616 - Moisturizing and lubricating compositions: The present invention is generally directed to moisturizing and lubricating compositions for use on the bodyfacing surface of an absorbent product or on one or both faces of a tissue product. The moisturizing and lubricating compositions comprise an emollient, a humectant, and immobilizing agent and a compatibilizing agent. Optionally, the... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090220617 - Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion: The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of reducing delays in the birth process and, thereby, complications resulting there from that may negatively affect the health and wellbeing of the mother and increase the incidence of stillbirths and/or... Agent: Foley And Lardner LLP Suite 500

20090220618 - Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide: A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises at least a polyanionic material and at least a source of hydrogen peroxide. The formulation can comprise an ophthalmically active agent... Agent: Bausch & Lomb Incorporated

20090220619 - Nutritional formulation: The present invention relates to nutritional supplements that provide an adult with essential vitamins and minerals that may be lacking in the adult's diet and prevent chronic diseases, such as osteoporosis. A number of combinations of nutrients in set ratios are provided to increase the body's ability to absorb and... Agent: Wyeth Patent Law Group

20090220620 - Functional fluid and a process for the preparation of the functional fluid: A functional fluid for the removal of contaminates such as but not limited to, acid causing components in gas, sulfur components and carbon oxides from fluid streams, and removal and treatment of NOX & SOX from post combustion emissions. Also described is the manufacturing process to produce the functional fluid... Agent: Honigman Miller Schwartz & Cohn LLP

20090220621 - Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination: A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a... Agent: Polsinelli Shughart PC

20090220622 - Use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders, and cosmetic or pharmaceutical composition containing same: The present invention relates to the use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders.... Agent: Merchant & Gould PC

20090220623 - Novel herbal acne control composition, method of manufacturing the same and use thereof: Disclosed herein a novel herbal acne control compositions comprising extracts of Swietenia mahagoni, Salix tetrasperma, Aloe vera and Curcuma longa and pharmaceutically acceptable excipients. Also disclosed are the methods of making the composition, formulating the same into different delivery systems and use thereof for the prevention of acne related skin... Agent: Knobbe Martens Olson & Bear LLP

20090220624 - Compositions comprising apocynin, ginkgo and ginger and uses thereof: A composition comprising ginkgo biloba or extract or component thereof; apocynin; and a gingerol. The composition may be used to treat diseases such as CF and COPD.... Agent: Knobbe Martens Olson & Bear LLP

20090220625 - Synergistic mixtures of bisabolol and ginger extract: Described is a formulation having a skin irritation-reducing action consisting of or comprising: bisabolol and a composition or compound chosen from the group consisting of a) substance mixtures obtainable from an extraction of ginger, b) substance mixtures obtainable from a separation of a ginger extract which comprise a compound which... Agent: Connolly Bove Lodge & Hutz LLP

20090220626 - Grape seed extract and its constituents for use as cyp2a6 inhibitors: The present invention relates to a use of grape seed extract or its constituents to treat conditions which benefit from an inhibition of cytochrome P450 2A6 (CYP2A6). In particular conditions which benefit from the inhibition of CYP2A6 are conditions which benefit from decreased metabolism of nicotine to cotinine, for example,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090220627 - Novel vascular endothelial growth factor expression inhibitors: The invention provides anti-aging agents, angiogenesis inhibitors and vascular endothelial growth factor (VEGF) expression inhibitors containing one or more galenicals selected from the group consisting of mukurossi peel extract, hazelnut extract, linden extract, coix extract, chlorella extract and tormentilla extract.... Agent: Fish & Richardson PC